17/02/2005 10081147

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS	19	FEB 16	STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

*ADISNEWS - Adis Newsletters 1983-present

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 11:05:45 ON 17 FEB 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.68	1.68

FILE 'REGISTRY' ENTERED AT 11:10:30 ON 17 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2005 HIGHEST RN 831913-30-5
DICTIONARY FILE UPDATES: 15 FEB 2005 HIGHEST RN 831913-30-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\100811471.str



chain nodes :
10 16 17 18
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15

chain bonds :
7-10 8-16 10-11 13-17 17-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-15 12-13 13-14 14-15

exact/norm bonds :
5-7 6-9 7-8 8-9 8-16 11-12 11-15 12-13 13-14 14-15 17-18
exact bonds :
7-10 10-11 13-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:12:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 175 TO ITERATE

100.0% PROCESSED 175 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2707 TO 4293
PROJECTED ANSWERS: 200 TO 800

L2 25 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:12:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4152 TO ITERATE

100.0% PROCESSED 4152 ITERATIONS 591 ANSWERS
SEARCH TIME: 00.00.01

L3 591 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	162.62	164.30

FILE 'CAPLUS' ENTERED AT 11:12:38 ON 17 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Feb 2005 VOL 142 ISS 8
FILE LAST UPDATED: 16 Feb 2005 (20050216/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 65 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:2190 CAPLUS
DOCUMENT NUMBER: 142:93676
TITLE: A preparation of sulfonamide substituted indolinones, useful as inhibitors of DNA dependent protein kinase (DNA-PK)
INVENTOR(S): Howlett, Anthony R.; Rice, Audie; Moshinsky, Deborah; Hammarsten, Ola
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004266843	A1	20041230	US 2004-793943		20040308
PRIORITY APPLN. INFO.:			US 2003-452549P	P	20030307

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of sulfonamide substituted indolinones of formula I [wherein: R1 and R2 are independently selected from H, (un)substituted Ph, thiazolyl, or alkyl, etc.; R3, R4, and R5 are independently selected from H or alkyl], useful as inhibitors of DNA dependent protein kinase (DNA-PK). The invention relates to the field of radiosensitizing agents which are capable of enhancing radiotherapy by inhibiting DNA-PK (DNA-protein kinase). For instance, sulfonamide substituted indolinone II was prepared via condensation of pyrrole derivative III and indole derivative IV. The prepared indolinone derivative V was found to inhibit DNA-PK (IC50 = 1.6 μM).

IT **342641-63-8P 775321-58-9P 775321-59-0P**
775321-60-3P 775321-68-1P 775321-69-2P
775321-70-5P 775321-73-8P 775321-75-0P
775321-77-2P 775321-78-3P 775321-80-7P
775321-81-8P 775322-06-0P 775322-07-1P
775322-08-2P 775322-12-8P 775322-13-9P
775322-14-0P 775322-15-1P 775322-18-4P
775322-19-5P 775322-20-8P 775322-25-3P
819044-92-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide substituted indolinones useful as inhibitors of DNA dependent protein kinase (DNA-PK))

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 775321-60-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-68-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 775321-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 775321-59-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(5-bromo-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775321-69-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,3-dihydro-5-methoxy-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 775321-70-5 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775321-73-8 CAPLUS
CN 1H-Pyrrole-3-acetamide,
5-[(Z)-[5-[[(3-chlorophenyl)methylamino]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-
morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-75-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-
morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-77-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,3-

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775321-81-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-

1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-
piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 775322-06-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dihydro-1H-indol-1-yl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-78-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-
pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-80-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-ethyl-4-methyl-N-[2-(1-
pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775322-07-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[1,2-dihydro-5-[(methylamino)sulfonyl]-2-
oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-08-2 CAPLUS
CN 1H-Pyrrole-3-acetamide,
5-[(Z)-[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-
oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-12-8 CAPLUS
CN 1H-Pyrrole-3-acetamide,
5-[(Z)-[5-[[(3-chlorophenyl)methylamino]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-
pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



RN 775322-13-9 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-14-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 775322-19-5 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-20-8 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-25-3 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775322-15-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-18-4 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(3-chlorophenyl)methylamino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 819044-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3-ethylpentyl)-5-[(Z)-[5-[(5-fluoro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

L4 ANSWER 2 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1121013 CAPLUS
TITLE: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
AUTHOR(S): Yee, Kevin W. H.; Schittenhelm, Marcus; O'Farrell, Anne-Marie; Town, Ajia R.; McGreevey, Laura; Bainbridge, Troy; Cherrington, Julie M.; Heinrich, Michael C.
CORPORATE SOURCE: Oregon Health and Science University Cancer Institute and Portland Veterans Affairs Medical Center, Portland, OR, USA
SOURCE: Blood (2004), 104(13), 4202-4209
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Fetal liver tyrosine kinase 3 internal tandem duplication (FLT3 ITD) mutations are the most common mol. abnormality associated with adult acute myeloid leukemia (AML). To exploit this mol. target, a number of potent and specific FLT3 kinase inhibitors have been developed and are currently being tested in early phase clin. trials of patients with refractory AML. To explore the efficacy of combining a FLT3 inhibitor with standard AML chemotherapy drugs, we tested the effect of combining the FLT3 inhibitor SU11248 with cytarabine or daunorubicin on the proliferation and survival of cell lines expressing either mutant (FLT3 ITD or FLT3 D835V) or wild-type (WT) FLT3. SU11248 had additive-to-synergistic inhibitory effects on FLT3-dependent leukemic cell proliferation when combined with cytarabine or daunorubicin. The synergistic interaction of SU11248 and the traditional antileukemic agents was more pronounced for induction of apoptosis. SU11248 inhibited the proliferation of primary AML myeloblasts expressing mutant FLT3 ITD but not WT FLT3 protein. Combining SU11248 and cytarabine synergistically inhibited the proliferation of primary AML myeloblasts expressing FLT3 ITD but not WT FLT3 protein. These data suggest that the addition of potent FLT3 inhibitors such as SU11248 to AML chemotherapy regimens could result in improved treatment results.

IT 557795-19-4, SU 11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-pos. leukemic cells)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1059176 CAPLUS
DOCUMENT NUMBER: 142:32986
TITLE: Use of a c-abl-, PDGFR-, or c-kit-tyrosine kinase inhibitor for the treatment of diabetes
INVENTOR(S): Hagerkvist, Robert Per; Welsh, Nils Richard
PATENT ASSIGNEE(S): Swed.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105763	A2	20041209	WO 2004-EP5679	20040526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			GB 2003-12086	A 20030527
			GB 2004-2682	A 20040206

GI



I

AB The invention discloses the use of a c-Abl-, PDGFR-, or c-kit-tyrosine kinase inhibitor, e.g. I, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes, including type I or type II diabetes.

IT 557795-19-4, SU 11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU 11248; c-abl-, PDGFR-, or c-kit-tyrosine kinase inhibitor for

L4 ANSWER 3 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
treatment of diabetes)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:995713 CAPLUS
DOCUMENT NUMBER: 141:420610
TITLE: Surface receptor complexes as biomarkers of disease and for determination of treatment with dimer-acting drugs
INVENTOR(S): Chan-Hui, Po-Ying; Dua, Rajiv; Mukherjee, Ali; Pidaparthi, Sailaja; Salimi-Moosavi, Hossein; Shi, Yining; Singh, Sharat
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U.S. Ser. No. 623,057.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 29
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229293	A1	20041118	US 2004-812619	20040330
US 2003013126	A1	20030116	US 2002-154042	20020521
US 2004126818	A1	20040701	US 2003-623057	20030717
US 2004197835	A1	20041007	US 2004-830543	20040422
PRIORITY APPLN. INFO.:			US 2002-154042	A2 20020521
			US 2002-398724P	P 20020725
			US 2003-459888P	P 20030401
			US 2003-623057	A2 20030717
			US 2003-494482P	P 20030811
			US 2003-508034P	P 20031001
			US 2003-512941P	P 20031020
			US 2003-523258P	P 20031118
			US 2001-292548P	P 20010521
			US 2001-334901P	P 20011024

AB The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amts. of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amts. of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or

L4 ANSWER 4 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compds. having releasable mol. tags that are specific for multiple components of one or more types of receptor dimers. After binding, mol. tags are released and sepd. from the assay mixt. for anal.

IT **557795-19-4**, SU11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface receptor complexes as biomarkers of disease or responsiveness to treatment)

RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 5 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:965067 CAPLUS
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			EP 2003-9587	A 20030429
			EP 2004-508	A 20040113
			EP 2004-1171	A 20040121

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT **557795-19-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU 11248; drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

L4 ANSWER 5 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **627908-92-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU 14813; drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 627908-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L4 ANSWER 6 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:905883 CAPLUS
DOCUMENT NUMBER: 141:361107
TITLE: Methods for the detection of cell surface receptor complexes as cancer biomarkers and therapeutic effectiveness of cleavage thereof
INVENTOR(S): Chan-Hui, Po-Ying; Salimi-Moosavi, Hossein; Shi, Yining; Singh, Sharat; Dua, Rajiv; Mukherjee, Ali; Pidaparthi, Sailaja
PATENT ASSIGNEE(S): Aclara Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 29
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004092353	A2	20041028	WO 2004-US9717		20040330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2004126818	A1	20040701	US 2003-623057		20030717
PRIORITY APPLN. INFO.:			US 2003-459888P	P	20030401
			US 2003-623057	A	20030717
			US 2003-494482P	P	20030811
			US 2003-508034P	P	20031001
			US 2003-512941P	P	20031020
			US 2003-523258P	P	20031118
			US 2002-398724P	P	20020725

AB The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amts. of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amts. of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compds. having releasable mol. tags that are specific for multiple components of one or more types of receptor dimers. After binding, mol. tags are release and sepd. from the assay mixt. for anal.

IT 557795-19-4, SU11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for detection of cell surface receptor complexes as cancer biomarkers and therapeutic effectiveness of cleavage thereof)

RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 7 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:902199 CAPLUS
DOCUMENT NUMBER: 141:374704
TITLE: Composition and uses of galectin antagonists to augment treatment of cancer or other proliferative disorders
INVENTOR(S): Chang, Yan; Sasak, Vodek
PATENT ASSIGNEE(S): Glycogenesys, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004091634	A1	20041028	WO 2004-US10675		20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2004023925	A1	20040205	US 2003-408723		20030407
US 2004223971	A1	20041111	US 2004-819901		20040407
PRIORITY APPLN. INFO.:			US 2003-408723	A	20030407
			US 2003-461006P	P	20030407
			US 2003-474562P	P	20030530
			US 2001-299991P	P	20010621
			US 2002-176235	A2	20020620

AB The present invention is directed to methods and compns. for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a 'galectin-3 inhibitor') so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.

IT 557795-19-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU 11248; composition and uses of galectin antagonists to augment treatment of cancer or other proliferative disorders)

L4 ANSWER 7 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:878170 CAPLUS
DOCUMENT NUMBER: 141:366237
TITLE: Preparation of indolinone compounds for treatment of excessive osteolysis
INVENTOR(S): Murray, Lesley; O'Farrell, Anne-Marie; Abrams, Tinya
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209937	A1	20041021	US 2004-780917	20040219
WO 2004075775	A2	20040910	WO 2004-US405283	20040223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, UG, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-448861P P 20030224
US 2004-780917 A 20040219

OTHER SOURCE(S): MARPAT 141:366237
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed is a method for treating excessive osteolysis in a patient, comprising administering to said patient an effective amount of a compound of formula (I) [wherein R = H, OH, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocyclyl, amino; R1 = alkyl, halo, aryl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heteroaryl, heterocyclyl, HO, COR8, NR9R10, NR9COR12, CONR9R10; R2 = alkyl, aryl, heteroaryl, COR8, SO2R''; (wherein R" = alkyl, aryl, heteroaryl, NR9R10, alkoxy); R5 = H, alkyl, aryl, haloalkyl, cycloalkyl, heteroaryl, heterocyclyl, HO, COR8, (CHR)rR11; X = O, S; p, r = 0-3; q = 0-2; wherein R8 = OH, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl, heterocyclyl; R9, R10 = H, alkyl, aryl, aminoalkyl, heteroaryl, cycloalkyl, heterocyclyl; or NR9R10 together forms a ring consisting of the ring atoms selected from the group consisting of C, N, O, and S; R11 = OH, NH2, mono- or disubstituted amino, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl, heterocyclyl; R12 = alkyl, aryl, heteroaryl, alkoxy, cycloalkyl, heterocyclyl; Z = OH, O-alkyl, NR3R4; wherein R3, R4 = H, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl; or NR3R4 forms a ring consisting of the ring atoms selected from the group consisting of CH2, N, O, and S, or Q1; wherein Y = CH2, O, N, S; Q = C, N; n = 0-4; m = 0-3] or salts thereof. These compds. are useful for treating excessive osteolysis, by inhibiting M-CSF mediated osteoclast development. They are useful for inhibiting phosphorylation of colony-stimulating factor-1 receptor (CSF1R), and for treating cancers that express CSF1R. Thus, in a study on bone metastasis of cancer, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (II) at 80 or 40 mg/kg per day for 21 days inhibited the growth of 435/HAL-luc breast cancer cells in bone by 89% in mice in 41 days after inoculation with cancer cells. Formulations, e.g. hard gelatin capsule contg. II, were described.

IT **356068-94-5P 356068-97-8P**, 5-[(3Z)-5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)amide **452104-42-6P**, 5-[(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-(3-diethylamino-2-hydroxypropyl)amide **452104-85-7P**,

5-[(3Z)-5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid {2-hydroxy-3-(morpholin-4-yl)propyl}amide **452104-86-8P**, 2,4-Dimethyl-5-[(3Z)-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrole-3-carboxylic acid {2-hydroxy-3-(morpholin-4-yl)propyl}amide **452104-87-9P**, 5-[(3Z)-5-Chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(morpholin-4-yl)propyl]amide **452104-88-0P**,

5-[(3Z)-5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(morpholin-4-yl)propyl]amide **452104-89-1P**, 2,4-Dimethyl-5-[(3Z)-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrole-3-carboxylic acid N-{2-hydroxy-3-([1,2,3]triazol-1-yl)propyl}amide **452104-90-4P**,

5-[(3Z)-5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(1H-[1,2,3]triazol-1-yl)propyl]amide **452104-91-5P**, 5-[(3Z)-5-Chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(1H-[1,2,3]triazol-1-yl)propyl]amide **452104-92-6P**, 5-[(3Z)-5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-hydroxy-3-(1H-[1,2,3]triazol-1-yl)propyl]amide **452105-23-6P**, 5-[(3Z)-5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[(2S)-2-hydroxy-3-(morpholin-4-yl)propyl]amide **452105-24-7P 499220-14-3P 557795-19-4P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-(2-diethylaminoethyl)amide **587879-12-7P**, (Z)-5-[(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indolinone compds. for treatment of excessive osteolysis, inhibiting phosphorylation of colony-stimulating factor-1 receptor (CSF1R), and treating cancers that express CSF1R)

RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356068-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-42-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-85-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-86-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-87-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 8 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-88-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-89-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-90-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 8 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 499220-14-3 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5
CMF C22 H27 F N4 O2



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).

L4 ANSWER 8 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-91-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-92-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 8 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 587879-12-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:857170 CAPLUS
DOCUMENT NUMBER: 141:350032
TITLE: Preparation of 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Liang, Congxin; Miller, Todd; Lipson, Kenneth E.
PATENT ASSIGNEE(S): Sugen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 58 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004204407	A1	20041014	US 2004-793952		20040308
PRIORITY APPLN. INFO.:			US 2003-452552P	P	20030307

OTHER SOURCE(S): MARPAT 141:350032
GI



I



II

AB The title compds. [I; R1 and R2 combine to form (un)substituted optionally fused heterocyclic ring; R3-R5 = H, alkyl, hydroxyalkyl, etc.; or R3 and R4 may combine to form a cyclic 6-membered alicyclic ring which may be

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 775321-60-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-68-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
substituted with one or more lower alkyl] that modulate the activity of protein kinases ("PKs") and are therefore useful in treating disorders related to abnormal PK activity (no biol. data), were prepd. General method of synthesis of the compds. I by condensation of oxindoles and aldehydes (prepn. of intermediates is given) is described. Eighty-two compds. I (e.g., II) were prepd. Pharmaceutical compns. comprising the compds. I, methods of treating diseases utilizing pharmaceutical compns. comprising these compds. and methods of prepg. them are also disclosed.
IT 775321-58-9P 775321-59-0P 775321-60-3P
775321-68-1P 775321-69-2P 775321-70-5P
775321-73-8P 775321-75-0P 775321-77-2P
775321-78-3P 775321-80-7P 775321-81-8P
775322-01-5P 775322-06-0P 775322-07-1P
775322-08-2P 775322-12-8P 775322-13-9P
775322-14-0P 775322-15-1P 775322-18-4P
775322-19-5P 775322-20-8P 775322-25-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-sulfonamido-substituted indolinone compds. as protein kinase inhibitors)
RN 775321-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 775321-59-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(5-bromo-2,3-dihydro-1H-indol-1-

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775321-69-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,3-dihydro-5-methoxy-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 775321-70-5 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775321-73-8 CAPLUS
CN 1H-Pyrrole-3-acetamide,
5-[(Z)-[5-[[(3-chlorophenyl)methylamino]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-
morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-75-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-
morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-77-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,3-

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775321-81-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-

1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-methyl-1-
piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 775322-01-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(5-fluoro-
2,3-dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dihydro-1H-indol-1-yl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-78-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-
pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775321-80-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-ethyl-4-methyl-N-[2-(1-
pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775322-06-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 775322-07-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[1,2-dihydro-5-[(methylamino)sulfonyl]-2-
oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-08-2 CAPLUS
CN 1H-Pyrrole-3-acetamide,
5-[(Z)-[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-
oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775322-12-8 CAPLUS
CN 1H-Pyrrole-3-acetamide,
5-[(Z)-[5-[[(3-chlorophenyl)methylamino]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-
pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-13-9 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA
INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 775322-19-5 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[1,2-dihydro-5-[(methylamino)sulfonyl]-2-
oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-20-8 CAPLUS
CN 1H-Pyrrole-3-acetamide,
5-[(Z)-[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-
oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-25-3 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-

[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 775322-14-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-
[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 775322-15-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 775322-18-4 CAPLUS
CN 1H-Pyrrole-3-acetamide,
5-[(Z)-[5-[[(3-chlorophenyl)methylamino]sulfonyl]-

1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-
dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 9 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 10 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:740292 CAPLUS
DOCUMENT NUMBER: 141:265970
TITLE: Polymorphs of pyrrole-substituted 2-indolinone protein kinase inhibitors
INVENTOR(S): Sun, Changquan; Foster, Todd P.; Han, Fusen; Hawley, Michael; Thamann, Tom
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076410	A2	20040910	WO 2004-US5281	20040223
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004259929	A1	20041223	US 2004-776337	20040212
PRIORITY APPLN. INFO.:			US 2003-448863P P	20030224
			US 2004-776337 A	20040212

AB The present invention relates to polymorphs of the 3-pyrrole-substituted 2-indolinone, 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (I). The phys. properties of polymorphs of I were determined by spectroscopic methods.
IT **753451-03-5**
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(polymorphs of pyrrole-substituted indolinone protein kinase inhibitors)
RN 753451-03-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 10 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

IT **356068-94-5**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymorphs of pyrrole-substituted indolinone protein kinase inhibitors)
RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 11 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:718281 CAPLUS
DOCUMENT NUMBER: 141:230695
TITLE: Semisolid oral formulations for immediate release containing indolylidenemethyl pyrrolepropionates
INVENTOR(S): Martini, Alessandro; Ciocca, Cristina; Gatti, Paolo
PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073592	A2	20040902	WO 2004-EP50058	20040130
WO 2004073592	A3	20041021		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			IT 2003-RM74 A	20030221

OTHER SOURCE(S): MARPAT 141:230695
GI



I

AB The present invention relates to a pharmaceutical composition suitable for oral
administration, in the form of semisolid matrix, comprising an active ingredient poorly soluble in water and present in a quantity of from 15 to
45% by weight of the percent composition of the pharmaceutical composition; a
surfactant agent constituted by a polyglycolized glyceride; and a pharmaceutically acceptable hydrophilic carrier. A solid dispersion based

L4 ANSWER 11 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
on Gelucire 44/14 contg. 10% SU 6668 (I) was stable, homogeneous and had a
dissoln. profile that assures that >90% of I is released within 45 min.
IT **748153-83-5**, SU 14813 Lmalate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
(Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(semisolid oral formulations for immediate release containing indolylidenemethyl pyrrolepropionates)
RN 748153-83-5 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-fluoro-1,2-dihydro-2-
oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 627908-92-3
CMF C23 H27 F N4 O4

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



IT **557795-19-4**, SU 11248
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(semisolid oral formulations for immediate release containing indolylidenemethyl pyrrolepropionates)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 11 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 12 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:565086 CAPLUS
DOCUMENT NUMBER: 141:123632
TITLE: Preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Cai, Sui Xiong; Zhang, Han-zhong; Kuemmerle, Jared D.; Zhang, Hong; Kemnitzer, William E.
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058253	A1	20040715	WO 2003-US40308	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004127521	A1	20040701	US 2003-737865	20031218
PRIORITY APPLN. INFO.:			US 2002-433953P P	20021218

OTHER SOURCE(S): MARPAT 141:123632
GI



AB Title compds. I [R1-3 = H, halo, haloalkyl, aryl, etc.; Q = S, O, amino; A = heterocycle, carbocycle] are prepared For instance, 3-amino-4-

L4 ANSWER 12 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

chlorobenzamidoxime (prepn. given) is reacted with 3-chlorothiophene-2-carbonyl chloride (pyridine, reflux, 50 min) to give II. II and other examples are potent caspase cascade activators and inducers of apoptosis in solid tumor cells, e.g., human breast cancer cell lines T-47D and ZR-75-1.

IT **557795-19-4**, SU11248
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 13 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:534300 CAPLUS
DOCUMENT NUMBER: 141:65094
TITLE: Substituted 1-benzoyl-3-cyano-pyrrolo[1,2-a]quinolines and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Cai, Sui Xiong; Drewe, John A.; Jiang, Sungchun; Kasibhatla, Shailaja; Kuemmerle, Jared Daniel; Sirisoma, Nilantha Sudath; Zhang, Han-Zhong
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055163	A2	20040701	WO 2003-US39550	20031212
WO 2004055163	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005014759	A1	20050120	US 2003-733229	20031212
PRIORITY APPLN. INFO.:			US 2002-432608P P	20021212

OTHER SOURCE(S): MARPAT 141:65094
AB The invention discloses substituted 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines and analogs thereof. Compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the compds. of the invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound prepn is described.

IT **557795-19-4**, SU 11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (benzoylcyanopyrroloquinolines and analogs as activators of caspases and inducers of apoptosis)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 13 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 14 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 557795-19-4, SU 11248
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KIT tyrosine kinase inhibitor; methods for assessing anti-cancer activity of KIT tyrosine kinase inhibitor, gastrointestinal stromal tumor treatment, and assessing cancer progression, using gene expression profiling)

RN 557795-19-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 14 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:452980 CAPLUS
DOCUMENT NUMBER: 141:33766
TITLE: Methods for assessing the anti-cancer activity of a KIT tyrosine kinase inhibitor, gastrointestinal stromal tumor treatment, and assessing cancer progression, using gene expression profiling
INVENTOR(S): Eisenberg, Burton; Von Mehren, Margaret; Frolov, Andrey; Godwin, Andrew
PATENT ASSIGNEE(S): Fox Chase Cancer Center, USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045545	A2	20040603	WO 2003-US36820	20031118
WO 2004045545	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-427326P P 20021118

AB The present invention provides novel methods for the treatment of cancer, methods for screening compds. having anti-cancer activity, and methods of assessing cancer progression. In accordance with the present invention, a method of assessing the anti-cancer activity of a KIT tyrosine kinase inhibitor in a biol. sample comprising a tumor cell is provided. In a preferred embodiment, the tumor is a gastrointestinal stromal tumor (GIST) and the KIT tyrosine kinase inhibitor is imatinib, SU11248 (Sugen Pharmaceuticals), or a pharmaceutically acceptable salt thereof. DNA microarrays revealed 148 genes that were differentially expressed between untreated and imatinib-treated human GIST cells, in vitro. One of these genes, Sprouty4A (SPRY4A) a regulator of tyrosine kinase-mediated signaling pathways, was dramatically down- regulated. A biomarker MAFbx was up-regulated in response to imatinib treatment. In addition, imatinib inhibited KIT phosphorylation without affecting the total level of KIT protein. The inventors proposed a method for determining the efficacy of an anticancer treatment comprising detection of an alteration in phosphorylation of a biomarker (such as decrease in GAB1 phosphorylation).

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:452964 CAPLUS
DOCUMENT NUMBER: 141:1206
TITLE: Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
INVENTOR(S): Abrams, Tinya; Murray, Lesley; Pryer, Nancy; Cherrington, Julie M.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045523	A2	20040603	WO 2003-US36526	20031114
WO 2004045523	A3	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

NL 1024779	A1	20040518	NL 2003-1024779	20031114
NL 1024779	C2	20041109		
US 2004152759	A1	20040805	US 2003-712296	20031114

PRIORITY APPLN. INFO.: US 2002-426386P P 20021115

OTHER SOURCE(S): MARPAT 141:1206
GI



I

AB The invention relates to a method of treating cancer by administering a combination of an indolinone compound with another chemotherapeutic agent.

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
The combination of an indolinone compd. I (R = H, OH, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocycle, amino; R1 = alkyl, halo, alkoxy, etc.; R2 = alkyl, aryl, heteroaryl, etc.; R5 = H, alkyl, aryl, haloalkyl, cycloalkyl, etc.; X = O, S; p = 0, 1, 2, 3; q = 0, 1, 2; Z = OH, -O-alkyl, -NR3R4; R3, R4 = H, alkyl, aryl, heteroaryl, cycloalkyl, heterocycle, or together with N form a ring) with another chemotherapeutic
agent provides an enhanced effect in treating cancer patients. Mice implanted with MX-1 human breast carcinoma fragments were treated with docetaxel and 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (prepn. given).

IT **627908-92-3P 674778-85-9P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(as indolinone compound; cancer therapy using combination administration
of indolinone compds. with chemotherapeutic agents for cell proliferation disorders)

RN 627908-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 674778-85-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
NAME)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX
NAME)



RN 356069-16-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT **342641-94-5 342641-94-5D**, acceptable salts, solvates, hydrates **346405-32-1 346405-32-1D**, acceptable salts, solvates, hydrates **356069-16-4 356069-16-4D**, acceptable salts, solvates, hydrates **452104-43-7 452104-43-7D**, acceptable salts, solvates, hydrates **452104-45-9 452104-45-9D**, acceptable salts, solvates, hydrates **515138-82-6 515138-82-6D**, acceptable salts, solvates, hydrates **627908-92-3D**, acceptable salts, solvates, hydrates **674778-85-9D**, acceptable salts, solvates, hydrates **697224-82-1**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as indolinone compound; cancer therapy using combination administration
of indolinone compds. with chemotherapeutic agents for cell proliferation disorders)

RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-16-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-43-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-43-7 CAPLUS

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-45-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-45-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 515138-82-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 515138-82-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 627908-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 674778-85-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 697224-82-1 CAPLUS
CN Butanedioic acid, hydroxy-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5
CMF C22 H27 F N4 O2



CM 2

CRN 6915-15-7
CMF C4 H6 O5

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **356068-97-8P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)amide **452104-42-6P 452104-85-7P 452104-86-8P 452104-87-9P 452104-88-0P 452104-89-1P 452104-90-4P 452104-91-5P 452104-92-6P 452105-23-6P 452105-24-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(cancer therapy using combination administration of indolinone compds. with chemotherapeutic agents for cell proliferation disorders)

RN 356068-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-42-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-85-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-86-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-87-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-88-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-89-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-90-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-91-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-92-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 15 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 16 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:252326 CAPLUS
DOCUMENT NUMBER: 140:276195
TITLE: Formulations comprising an indolinone compound
INVENTOR(S): Gatti, Paolo
PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024127	A2	20040325	WO 2003-IB5293	20030910
WO 2004024127	A3	20040603		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
NL 1024261	A1	20040311	NL 2003-1024261	20030910
US 2004229930	A1	20041118	US 2003-658801	20030910
PRIORITY APPLN. INFO.:			US 2002-421133P	P 20020910

OTHER SOURCE(S): MARPAT 140:276195

AB The present invention features formulations of indolinones suitable for parenteral or oral administration. The formulations and the compds. themselves are useful for the treatment of protein kinase related disorders. For example, 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino)-amide (I) was wet granulated with mannitol, croscarmellose sodium and polyvinylpyrrolidone, the granules were dried, blended with magnesium stearate, and filled in capsules; each capsule contained 50 mg, 75 mg, or 200 mg I.

IT **342641-94-5 452104-85-7 452105-23-6 452105-24-7 499220-14-3 627908-92-3 674778-85-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of oral and parenteral compns. of indolinone compound)

RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-85-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 16 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 499220-14-3 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5
CMF C22 H27 F N4 O2



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 627908-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 16 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 674778-85-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L4 ANSWER 17 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 422 THERE ARE 422 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:197494 CAPLUS
DOCUMENT NUMBER: 141:235330
TITLE: Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy
AUTHOR(S): Smith, John K.; Mamoon, Naila M.; Duhe, Roy J.
CORPORATE SOURCE: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, 39216-4505, USA
SOURCE: Oncology Research (2003), 14(4/5), 175-225
CODEN: ONREE8; ISSN: 0965-0407
PUBLISHER: Cognizant Communication Corp.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Targeted protein-tyrosine kinase inhibitors (PTKIs) comprise a new, rapidly evolving class of low mol. weight anticancer drugs. Two members of this class, imatinib (Gleevec) and gefitinib (Iressa), are currently approved for market use in the United States. This review discusses the scientific history behind these two PTKI drugs, including the role of the targeted kinase in cancer etiol., the biochem. of selective inhibition, the evaluation of clin. efficacy, and the mechanisms whereby drug resistance has emerged. Other PTKIs undergoing clin. evaluation are also described, including epidermal growth factor receptor kinase inhibitors (erlotinib, PKI166, and CI-1033) and PTKIs designed to disrupt tumor vascularization (SU5416, SU6668, SU11248, PTK787, and ZD6474). How might one apply current knowledge to the efficient development of new agents that would target as-yet-unexploited oncogenic PTKs such as chimeric anaplastic leukemia kinases or Janus kinases. Ideally, the targets should contain structurally distinct drug interaction epitopes, although it is not necessary that these epitopes be unique to a single target, because effective drugs may inhibit multiple kinases involved in an oncogenic process. Oral availability is a highly desirable feature because daily oral administration can maintain a sustained efficacious plasma concentration, whereas intermittent parenteral administration may not. Perhaps most importantly, one must verify the presence of an appropriate mol. target on a case-by-case basis before selecting a patient for PTKI therapy. Thus, the development of molecularly targeted diagnostic tools will be crucial to the ultimate success of molecularly targeted PTKI therapy.
IT **557795-19-4**, SU 11248
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU 11248; epidermal growth factor receptor kinase inhibitor CI-1033 is designed to disrupt tumor vascularization SU11248 and used in treatment of cancer therapy)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 18 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:182368 CAPLUS
DOCUMENT NUMBER: 140:229401
TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands
INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043388	A1	20040304	US 2002-234985	20020903
US 2003165873	A1	20030904	US 2002-91177	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPLN. INFO.:			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2002-91177	A2 20020304
			US 2001-336962P	P 20011203
			WO 2002-US6677	A2 20020304
			US 2002-234985	A2 20020903
			WO 2002-US33052	A2 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene gycol moiety to dexamethasone, is described.
IT **295799-47-2D**, conjugates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
RN 295799-47-2 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 19 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 19 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:172077 CAPLUS
DOCUMENT NUMBER: 140:357149
TITLE: Amidations Using N,N'-Carbonyldiimidazole: Remarkable Rate Enhancement by Carbon Dioxide
AUTHOR(S): Vaidyanathan, Rajappa; Kalthod, Vikram G.; Ngo, Duc P.; Manley, Jerad M.; Lapekas, Sean P.
CORPORATE SOURCE: Chemical Research and Development, Pfizer Inc., Kalamazoo, MI, 49001, USA
SOURCE: Journal of Organic Chemistry (2004), 69(7), 2565-2568
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Carbon dioxide catalyzes the reaction of imidazolides with amines to form amides. A substantial rate enhancement is observed in the presence of CO2
compared to the CO2-free case. The scope and limitations of this reaction
are discussed. For example, amidation of 5-formyl-2,4-dimethyl-1H-pyrrole-
3-carboxylic acid (I) in the presence of 1,1'-carbonylbis[1H-imidazole] and carbon dioxide gave N-[2-(diethylamino)ethyl]-5-[[[2-(diethylamino)ethyl]imino]methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (II). Hydrolysis of II gave N-[2-(diethylamino)ethyl]-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide. Reaction of II with 5-fluoro-1,3-dihydro-2H-indol-2-one gave N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide. The effect of 1-[(2,4-diethyl-1H-pyrrol-3-yl)carbonyl]-1H-imidazole on the amidation kinetics was evaluated.
IT **342641-94-5P**, N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of carboxamides from carboxylic acids and amines in presence of
carbonylbis[imidazole] and carbon dioxide as catalyst)
RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:162557 CAPLUS
DOCUMENT NUMBER: 140:195469
TITLE: Phosphatidylinositol 3-kinase antagonists as radiosensitizers
INVENTOR(S): Hallahan, Dennis E.; Tan, Jiahuai
PATENT ASSIGNEE(S): Vanderbilt University, USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016211	A2	20040226	WO 2003-US25015	20030808
WO 2004016211	A3	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-401864P P 20020808

AB A method for increasing radiosensitivity of a target tissue in a subject via administration of a phosphatidylinositol 3-kinase (PI3K) antagonist to
a target tissue in a subject. Also provided are methods for suppressing tumor growth and for inhibiting tumor blood vessel growth via administration of a PI3K antagonist.
IT **557795-19-4**, SU11248
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PI3K antagonists as radiosensitizers targeted to tumor vascular endothelium)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 21 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:157243 CAPLUS
DOCUMENT NUMBER: 141:116612
TITLE: Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor
AUTHOR(S): Morimoto, Alyssa M.; Tan, Nguyen; West, Kristina; McArthur, Grant; Toner, Guy C.; Manning, William C.; Smolich, Beverly D.; Cherrington, Julie M.
CORPORATE SOURCE: Department of Preclinical Research and Exploratory Development, SUGEN, Inc., South San Francisco, CA, 94080, USA
SOURCE: Oncogene (2004), 23(8), 1618-1626
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Biomarkers that indicate biol. activity and/or efficacy are a potentially useful tool in the development of molecularly targeted therapeutics. It is useful, though challenging, to identify biomarkers during preclin. development in order to impact decision-making during early clin. development. SU11248 is an oral, selective multitargeted tyrosine kinase inhibitor currently in Phase II oncol. clin. trials. It exhibits direct antitumor and antiangiogenic activity via inhibition of the receptor tyrosine kinases PDGFR, VEGFR, KIT and FLT3. To identify clin. translatable biomarkers of SU11248 activity, expression profiling was performed on Colo205 human xenograft tumors following treatment with SU11248. Over 100 transcripts changed in abundance in SU11248 as compared to vehicle-treated tumors. Nine candidate transcripts, chosen based on putative function, were also analyzed and validated by TaqMan. One such potential biomarker, cadherin-11, was further evaluated at the protein level and was found to have increased expression in xenograft tumors after SU11248 treatment. Interestingly, cadherin-11 expression was also detected via immunohistochem. anal. of archived solid tumors, indicating the tech. feasibility of translating this putative biomarker to clin. studies. Importantly, SU11248 treatment also resulted in increased expression of cadherin-11 protein in human tumor biopsies in three out of seven patients examined and confirms the feasibility of using transcriptional profiling of preclin. models to identify clin. translatable biomarkers.

IT **557795-19-4**, SU11248
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 21 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:143270 CAPLUS
DOCUMENT NUMBER: 140:197593
TITLE: PDGFRα oncokinase fusion protein associated with hyperproliferative disease and as imatinib mesylate target in EOL-1 cell
INVENTOR(S): Briesewitz, Roger; Griffin, John H.
PATENT ASSIGNEE(S): Theravance, Inc., USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004015082	A2	20040219	WO 2003-US24992	20030808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004045044	A1	20040304	US 2003-637356	20030808
PRIORITY APPLN. INFO.:			US 2002-402330P P	20020809
			US 2003-440491P P	20030116

AB Oncokinase fusion protein associated with hyperproliferative disorders are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. The invention provides sequence of protein NM_030917 fused with platelet-derived growth factor receptor α from human. The invention also identified deletion of 1 megabase fuses NM_030917 and exon 12 of PDGFRα on human chromosome 4. Also provided are methods of diagnosing disease conditions associated with the fusion polypeptides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.

IT **557795-19-4**, SU11248
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reducing activity of fusion protein by; PDGFRα oncokinase fusion protein associated with hyperproliferative disease and as imatinib mesylate target in EOL-1 cell)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 22 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 23 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:120755 CAPLUS
DOCUMENT NUMBER: 140:163705
TITLE: Process for preparation of isotopically labeled indolinone derivatives
INVENTOR(S): Giribone, Danilo; Pignatti, Alberto; Fontana, Erminia
PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012776	A1	20040212	WO 2003-EP50340	20030728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2002-78164	A 20020801

OTHER SOURCE(S): MARPAT 140:163705
GI



AB This invention pertains to a method for producing isotopically labeled [14C] indolinone derivs. with general formula of I [wherein R = alkyl, alkoxy, or halo; R1 = (un)substituted alkyl or CONH2; m = 0-4; n = 0-3] or pharmaceutically acceptable salts. For example, H14CONMe2 was reacted with 2,4-dimethylpyrrole in diphosphoryl chloride to give 3,5-dimethyl-1H-pyrrole-2-[14C]carboxaldehyde (49%). The above aldehyde was reacted with oxindole in EtOH in the presence of pyrrolidine to afford II (54%).
IT **656253-79-1P 656253-81-5P 656253-83-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 23 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 23 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of isotopically labeled indolinone derivs.)
RN 656253-79-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 656253-81-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 656253-83-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:100803 CAPLUS
DOCUMENT NUMBER: 140:139483
TITLE: Method for enhancing the effectiveness of therapies of hyperproliferative diseases
INVENTOR(S): Chang, Yan; Sasak, Vodek
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004023925	A1	20040205	US 2003-408723	20030407
US 2003013681	A1	20030116	US 2002-176235	20020620
US 6680306	B2	20040120		
US 2004043962	A1	20040304	US 2003-657383	20030908
WO 2004091634	A1	20041028	WO 2004-US10675	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-299991P	P 20010621
			US 2002-176235	A2 20020620
			US 2003-408723	A 20030407
			US 2003-461006P	P 20030407
			US 2003-474562P	P 20030530

AB The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.
IT **557795-19-4**, SU11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for enhancing effectiveness of therapies of hyperproliferative diseases)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry as shown.



L4 ANSWER 25 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 25 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:92033 CAPLUS
DOCUMENT NUMBER: 141:94116
TITLE: Powder-in-Bottle Formulation of SU011248. Enabling Rapid Progression into Human Clinical Trials
AUTHOR(S): Sistla, Anand; Sunga, Alan; Phung, Kenneth; Koparkar, Arun; Shenoy, Narmada
CORPORATE SOURCE: Pharmacia Company, Sugen Inc., San Francisco, CA, 94080, USA
SOURCE: Drug Development and Industrial Pharmacy (2004), 30(1), 19-25
CODEN: DDIPD8; ISSN: 0363-9045
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB SU011248 is an oral, multitargeted receptor tyrosine kinase inhibitor (anti PDGFR, VEGFR, Kit, and Flt3) for the treatment of solid tumors. The powder-in-bottle (PIB) approach was used to accelerate development and introduction into Phase I clin. trials. This approach consists of extemporaneously compounding the active pharmaceutical ingredient (API) into a solution or a suspension in the clinic prior to oral administration. The development consisted of physico-chem. assessment, constitution fluid selection, weighing and dosing validation, and stability evaluation of API, before and after constitution with the fluid. Of the oral liqs. evaluated, apple juice was selected as the constitution fluid. Particle size of SU011248 had an impact on the weighing validation and the dissoln. time. Particle size specifications of breadth d90<180 μm and length d90<750 μm were set to achieve pharmaceutical acceptability. Dosing validation studies showed complete recovery of SU011248 from the bottle over a dose range of 10 to 2200 mg. SU011248 is stable as the solid API. Following constitution with apple juice, the product is stable through the predicted duration of compounding and dosing at the clin. site. This approach provided a high degree of dosing flexibility during the initial phase of clin. trials. Addnl., the PIB approach reduced the time and API required for clin. development and supplies to < 2 mo and < 100 gm, resp.

IT **557795-19-4**, SU 11248
RL: PKT (Pharmacokinetics); PRP (Properties); BIOL (Biological study)
(powder-in-bottle formulation of SU011248. enabling rapid progression into human clin. trials)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 26 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:41213 CAPLUS
DOCUMENT NUMBER: 140:105249
TITLE: Combination of mTOR inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
INVENTOR(S): Neel, Benjamin G.; Mohi, Golam
PATENT ASSIGNEE(S): Beth Israel Deaconess Medical Center, USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004644	A2	20040115	WO 2003-US20972	20030703
WO 2004004644	A3	20040506		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
US 2002-394029P	P	20020705
US 2002-412402P	P	20020920

AB The invention features methods and compns. including an mTOR inhibitor and a tyrosine kinase inhibitor for reducing the proliferation of and enhancing the apoptosis of neoplastic cells. The addition of an MEK inhibitor to this combination further enhances the effectiveness of this therapeutic method.

IT **557795-19-4**, SU11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of mTOR inhibitor and tyrosine kinase inhibitor for cancer therapy)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 26 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 27 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:20448 CAPLUS
DOCUMENT NUMBER: 140:87676
TITLE: Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Tseng, Ben; Sirisoma, Nilantha Sudath; Cai, Sui Xiong; Zhang, Han-Zhong; Kasibhatla, Shailaja; Ollis, Kristin P.; Drewe, John A.
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002428	A2	20040108	WO 2003-US20668	20030701
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004082066	A1	20040429	US 2003-609670	20030701
PRIORITY APPLN. INFO.:			US 2002-392358P	P 20020701
			US 2002-413649P	P 20020926

OTHER SOURCE(S): MARPAT 140:87676
AB The invention is directed to derivs. of gambogic acid and analogs thereof.
Exemplary gambogic acid derivs. of the present invention include, among others, derivs. substituted in the C10 and C28 positions of gambogic acid.
The present invention also relates to the discovery that certain preferred
compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.
IT **557795-19-4**, SU11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivs. of gambogic acid and analogs as activators of caspases and inducers of apoptosis)
RN 557795-19-4 CAPLUS

L4 ANSWER 27 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 28 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:967557 CAPLUS
DOCUMENT NUMBER: 140:174343
TITLE: Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction
AUTHOR(S): Baratte, S.; Sarati, S.; Frigerio, E.; James, C. A.; Ye, C.; Zhang, Q.
CORPORATE SOURCE: Global Drug Metabolism, Nerviano, 20014, Italy
SOURCE: Journal of Chromatography, A (2004), 1024(1-2), 87-94
CODEN: JCRAEY; ISSN: 0021-9673
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB SU11248 is a potent inhibitor of PDGFR, VEGFR, KIT, and Flt3, and is currently under Phase I clin. evaluation as an anticancer drug. A sensitive and specific anal. method for the quantitation of SU11248 and its metabolite in several monkey tissues (liver, kidney, brain and white fat) using LC-MS-MS following semi-automated liquid-liquid extraction (LLE) was
developed and validated. Amts. of 50 mg of tissue were homogenized using an ultrasonic processor. After addition of the stable labeled internal standard
(IS) and ammonium hydroxide (0.3%), samples were extracted with 2.5 mL of tert-Bu Me ether. Following centrifugation, aliquots of 1.8 mL of the organic phase were transferred into a 96-well plate. The Packard Multiprobe
II robotic liquid handler was used to perform all steps mentioned above. The organic phase was dried and the residue was reconstituted with 800 µL
of 15 mM ammonium formate buffer solution (pH 3.25) using a Tomtec Quadra 96
workstation. Aliquots of 10 µL of the resulting solution were injected into the LC-MS-MS system. A Symmetry Shield C8 column (50 mm×2.1 mm, 3.5 µm) was used to perform the chromatog. anal. The mobile phase was 15 mM ammonium formate buffer solution (pH 3.25)-MeCN (74:26 (volume/volume))
with a flow-rate of 0.35 mL/min. Retention times of the metabolite and SU11248 were .apprx.2.5 and 3.5 min, resp. Total cycle time was 5 min. MS detection used the Applied Biosystems-MDS Sciex API 3000 with TurboIonSpray interface and multiple reaction monitoring (MRM) operated in
pos. ion mode. The method was validated for both compds. over the calibration range of .apprx.2 and 2000 ng/g. The suitability and robustness of the method for in vivo samples were confirmed by anal. of monkey tissues from animals dosed with SU11248.
IT **557795-19-4**, SU11248 **557795-19-4D**, SU11248, metabolite
RL: ANT (Analyte); ANST (Analytical study)
(quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph
with tandem mass spectrometry following semi-automated liquid-liquid extraction)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 29 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:949777 CAPLUS
DOCUMENT NUMBER: 141:64493
TITLE: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
AUTHOR(S): Murray, Lesley J.; Abrams, Tinya J.; Long, Kelly R.; Ngai, Theresa J.; Olson, Lisa M.; Hong, Weiru; Keast, Paul K.; Brassard, Jacqueline A.; O'Farrell, Anne Marie; Cherrington, Julie M.; Pryer, Nancy K.
CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, USA
SOURCE: Clinical & Experimental Metastasis (2003), 20(8), 757-766
CODEN: CEXMD2; ISSN: 0262-0898
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of the study was to investigate inhibitory effects of the receptor tyrosine kinase (RTK) inhibitor SU11248 against CSF-1R and osteoclast (OC) formation. We developed an in vivo model of breast cancer metastasis to evaluate efficacy of SU11248 against tumor growth and tumor-induced osteolysis in bone. The in vitro effects of SU11248 on CSF-1R phosphorylation, OC formation and function were evaluated. Effects on 435/HAL-Luc tumor growth in bone were monitored by in vivo bioluminescence imaging (BLI), and inhibition of osteolysis was evaluated by measurement of serum pyridinoline (PYD) concentration and histol. Phosphorylation of the receptor for M-CSF (CSF-1R) expressed by NIH3T3 cells was inhibited by SU11248 with an IC50 of 50-100 nM, consistent with CSF-1R belonging to the class III split kinase domain RTK family. The early M-CSF-dependent phase of in vitro murine OC development and function were inhibited by SU11248 at 10-100 nM. In vivo inhibition of osteolysis was confirmed by significant lowering of serum PYD levels following SU11248 treatment of tumor-bearing mice (P=0.047). Using BLI, SU11248 treatment at 40 mg/kg/day for 21 days showed 64% inhibition of tumor growth in bone (P=0.006), and at 80 mg/kg/day showed 89% inhibition (P=0.001). Collectively, these data suggest that SU11248 may be an effective and tolerated therapy to inhibit growth of breast cancer bone metastases, with the addnl. advantage of inhibiting tumor-associated osteolysis.
IT **557795-19-4**, SU 11248
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in mouse breast cancer bone metastasis model and mechanisms involved)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 29 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry as shown.



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 30 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:943094 CAPLUS
DOCUMENT NUMBER: 141:33400
TITLE: Proof of Target for SU11654: Inhibition of KIT Phosphorylation in Canine Mast Cell Tumors
AUTHOR(S): Pryer, Nancy K.; Lee, Leslie B.; Zadovaskaya, Regina; Yu, Xiaoming; Sukbuntherng, Juthamas; Cherrington, Julie M.; London, Cheryl A.
CORPORATE SOURCE: SUGEN,Inc, South San Francisco, CA, USA
SOURCE: Clinical Cancer Research (2003), 9(15), 5729-5734
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB PURPOSE: The purpose of this study was to evaluate the effect of the receptor tyrosine kinase inhibitor SU11654 on the activity of its mol. target KIT in canine mast cell tumors (MCT) and correlate target inhibition with mutational status of the c-kit juxtamembrane domain and SU11654 plasma concentration Exptl. Design: Tumor biopsies were obtained from dogs with advanced MCTs before and 8 h after administration of a single oral dose of SU11654, previously shown to be active in dogs with MCTs. Blood samples were taken to determine the plasma concentration of SU11654. Levels of phosphorylated KIT and ERK1/2 were assessed in tumor biopsies by Western blot. Tumors were analyzed by PCR for the presence or absence of an internal tandem duplication (ITD) in the juxtamembrane domain of c-kit. RESULTS: Fourteen dogs with advanced MCTs were enrolled in the study; 11 of these were evaluable for KIT target modulation (the remaining tumor specimens had inevaluable amts. of total KIT protein). Of these, eight MCTs showed reduced levels of phosphorylated KIT relative to total KIT after treatment with SU11654, compared with pretreatment biopsies. All four evaluable MCTs expressing ITD mutant c-kit showed modulation of KIT phosphorylation, as did four of seven tumors expressing non-ITD c-kit. Phosphorylated ERK1/2 was modulated in seven tumors; this did not correlate with inhibition of KIT phosphorylation. CONCLUSION: SU11654 treatment at the efficacious dose results in inhibition of KIT phosphorylation in canine MCTs.
IT **356068-94-5**, SU11654
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU11654 effect on activity of mol. target KIT in canine mast cell tumors)
RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 30 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:943061 CAPLUS
DOCUMENT NUMBER: 140:399449
TITLE: An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients
AUTHOR(S): O'Farrell, Anne-Marie; Foran, James M.; Fiedler, Walter; Serve, Hubert; Paquette, Ron L.; Cooper, Maureen A.; Yuen, Helene A.; Louie, Sharianne G.; Kim, Heidi; Nicholas, Susan; Heinrich, Michael C.; Berdel, Wolfgang E.; Bello, Carlo; Jacobs, Mark; Scigalla, Paul; Manning, William C.; Kelsey, Stephen; Cherrington, Julie M.
CORPORATE SOURCE: SUGEN Inc., South San Francisco, CA, USA
SOURCE: Clinical Cancer Research (2003), 9(15), 5465-5476
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB PURPOSE: Obtaining direct and rapid proof of mol. activity in early clin. trials is critical for optimal clin. development of novel targeted therapies.
SU 11248 is an oral multitargeted kinase inhibitor with selectivity for fms-related tyrosine kinase 3/Flk2 (FLT3), platelet-derived growth factor receptor α/β, vascular endothelial growth factor receptor 1/2, and KIT receptor tyrosine kinases. FLT3 is a promising candidate for targeted therapy in acute myeloid leukemia (AML), because activating mutations occur in up to 30% of patients. We conducted an innovative single-dose clin. study with a primary objective to demonstrate inhibition of FLT3 phosphorylation by SU 11248 in AML. Exptl. Design: Twenty-nine AML patients each received a single dose of SU 11248, escalated from 50 to 350 mg, in increments of 50 mg and cohorts of three to six patients. FLT3 phosphorylation and plasma pharmacokinetics were evaluated at seven time points over 48 h after SU 11248 administration, and FLT3 genotype was determined Study drug-related adverse events occurred in 31% of patients, mainly grade 1 or 2 diarrhea and nausea, at higher dose levels. RESULTS: Inhibition of FLT3 phosphorylation was apparent in 50% of FLT3-wild-type (WT) patients and in 100% of FLT3-mutant patients. FLT3 internal tandem duplication (ITD) mutants showed increased sensitivity relative to FLT3-WT, consistent with preclin. predictions. The primary end point, strong inhibition of FLT3 phosphorylation in >50% patients, was reached in 200 mg and higher dose cohorts. Downstream signaling pathways were also inhibited; signal transducer and activator of transcription 5 (STAT5) was reduced primarily in internal tandem duplication patients and at late time points in FLT3-WT patients, whereas extracellular signal-regulated kinase (ERK) activity was reduced in the majority of patients, independent of FLT3 inhibition. CONCLUSIONS: This novel translational study bridges preclin. models to the patient setting and provides the first evidence of anti-FLT3 activity in patients. Proof of target inhibition accomplishes a crucial milestone in the development of novel oncol. therapeutics.

IT **557795-19-4**, SU 11248
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(SU 11248 FLT3 phosphorylation inhibition in acute myeloid leukemia patients)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:931518 CAPLUS
DOCUMENT NUMBER: 140:689
TITLE: Genes showing altered patterns of expression in response to inhibition of tyrosine kinases and their use in screening kinase inhibitors
INVENTOR(S): Morimoto, Alyssa; Deprimo, Samuel; O'Farrell, Anne-Marie; Smolich, Beverly D.; Manning, William C.; Walter, Sarah A.; Schilling, James Walter, Jr.; Cherrington, Julie
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 408 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097854	A2	20031127	WO 2003-US15711	20030519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004018528	A1	20040129	US 2003-440464	20030519
PRIORITY APPLN. INFO.:			US 2002-380872P	P 20020517
			US 2003-448874P	P 20030224
			US 2003-448922P	P 20030224

OTHER SOURCE(S): MARPAT 140:689

AB Genes that are regulated by tyrosine kinase-dependent signal transduction pathways are identified as markers for the screening of inhibitors of kinase activity. The change in levels of either the protein or mRNA in a suitable test system may be used to assess the effectiveness of a test compound as an inhibitor of a tyrosine kinase activity. The invention also relates to novel methods, wherein a change in the level of at least one biomarker in a mammal exposed to a compound, compared to the level of the biomarker(s) in a mammal that has not been exposed to the compound, indicates whether the mammal is being exposed to, or is experiencing or will experience a therapeutic or toxic effect in response to, a compound that inhibit tyrosine kinase activity.

IT **342641-63-0 342641-64-9 342641-94-5**
346405-32-1 356068-82-1 356068-90-1
515138-82-6 627908-83-2 627908-84-3
627908-85-4 627908-86-5 627908-87-6
627908-92-3 627908-93-4 627908-94-5
627908-95-6
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as tyrosine kinase inhibitor; genes showing altered patterns of

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
expression in response to inhibition of tyrosine kinases and their use in screening kinase inhibitors)

RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-90-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 515138-82-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 627908-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 627908-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 627908-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 627908-86-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry unknown.



RN 627908-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 627908-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 627908-95-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 627908-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 627908-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 33 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:860154 CAPLUS
DOCUMENT NUMBER: 140:122316
TITLE: Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans
AUTHOR(S): Moss, Katherine G.; Toner, Guy C.; Cherrington, Julie M.; Mendel, Dirk B.; Laird, A. Douglas
CORPORATE SOURCE: Department of Preclinical Research and Exploratory Development, SUGEN, Inc., South San Francisco, CA, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2003), 307(2), 476-480
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Deregulated activation of the KIT receptor tyrosine kinase has been implicated in several human cancers and in inflammation, making it an attractive target for therapeutic intervention. Conversely, deficiencies in KIT signaling have been implicated in human and animal hair pigmentation disorders, reflecting a role for KIT in the development and function of melanocytes. The goal of this study was to explore the potential utility of hair depigmentation as a biol. readout for systemic inhibition of KIT by SU11248 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethylamide), an oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity through targeting platelet-derived growth factor receptors, vascular endothelial growth factor receptors, KIT, and FLT3. Oral SU11248 treatment induced dose-dependent depigmentation of newly regrown hair in depilated C57BL/6 mice. Similar effects were seen after administration of a KIT-neutralizing antibody. SU11248-induced hair depigmentation was reversible with cessation of treatment. Histol. and immunohistochem. evaluation of mouse skin samples supported these observations and revealed that SU11248 has no effect on levels of KIT-pos. melanocytes associated with hair follicles, indicating that the inhibitory effect is at the level of melanocyte function rather than their development/survival. Similar hair depigmentation has been noted in several cancer patients receiving SU11248 in phase I trials. Strikingly, patient scalp hair exhibits bands of depigmentation and pigmentation that correspond, resp., to periods of treatment and dosing rest periods. These data demonstrate that hair pigmentation can serve as a dose-dependent, dynamic, biol. readout for KIT inhibition in mice, and, apparently, in humans.

IT **557795-19-4**, SU11248
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hair depigmentation is a biol. readout for pharmacol. inhibition of KIT in mice and humans)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:844931 CAPLUS
DOCUMENT NUMBER: 140:192417
TITLE: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
AUTHOR(S): Abrams, Tinya J.; Murray, Lesley J.; Pesenti, Enrico; Walker Holway, Vicky; Colombo, Tina; Lee, Leslie B.; Cherrington, Julie M.; Pryer, Nancy K.
CORPORATE SOURCE: Preclinical Research and Experimental Development, SUGEN, Inc., South San Francisco, CA, USA
SOURCE: Molecular Cancer Therapeutics (2003), 2(10), 1011-1021
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB SU11248 is an oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities through targeting platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and FLT3, the first three of which are expressed in human breast cancer and/or its supporting tissues. The purpose of the present studies was to demonstrate the potent anticancer activity of SU11248 alone or in combination with conventional cytotoxic agents against several distinct preclin. models of breast cancer. SU11248 was administered as a monotherapy to (1) mouse mammary tumor virus-v-Ha-ras mice and 7,12-dimethylbenz(a)anthracene-treated rats bearing mammary tumors and (2) mice bearing human breast cancer xenografts of s.c. MX-1 tumors and osseous metastasis of a MDA-MB-435-derived cell line (435/HAL-Luc). SU11248 was also administered in combination with docetaxel both in xenograft models and in combination with 5-fluorouracil and doxorubicin in the MX-1 model. SU11248 treatment potently regressed growth of mammary cancers in mouse mammary tumor virus-v-Ha-ras transgenic mice (82% regression) and 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats (99% regression at the highest dose; $P < 0.05$ for both). This agent also inhibited MX-1 tumor growth by 52%, with markedly enhanced anticancer effects when administered in combination with docetaxel, 5-fluorouracil, or doxorubicin compared with either agent alone ($P < 0.05$). SU11248 treatment in combination with docetaxel effectively prolonged survival of mice, with 435/HAL-Luc cancer xenografts established in bone compared with either agent alone ($P < 0.05$). These results demonstrate that SU11248 is effective in preclin. breast cancer models and suggest that it may be useful in the treatment of breast cancer in the clinic.

IT **557795-19-4**, SU11248
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor tyrosine kinase inhibitor SU11248 for treatment of breast cancer)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:719299 CAPLUS
DOCUMENT NUMBER: 139:240339
TITLE: Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
INVENTOR(S): Wakabayashi, Toshiaki; Ono, Naoto; Semba, Taro; Haneda, Toru
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074045	A1	20030912	WO 2003-JP2492	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1481678	A1	20041201	EP 2003-743594	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			JP 2002-59471	A 20020305
			WO 2003-JP2492	W 20030304

OTHER SOURCE(S): MARPAT 139:240339
GI



AB It is intended to provide compns. and kits for treating tumor whereby the angiogenesis inhibitory activity and the antitumor activity of a sulfonamide-containing heterocyclic compound represented by the following

L4 ANSWER 35 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
formula (I) can be more effectively exerted. By combining with a VEGF inhibitor or an FGF inhibitor, the sulfonamide-contg. heterocyclic compd. can be effectively employed in treating cancer.
IT **557795-19-4**, SU11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitors)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:678808 CAPLUS
DOCUMENT NUMBER: 139:214331
TITLE: Process for preparing aminocarbonylpyrrolylmethylidene indolinones from indolinones, imidazolcarbonylpyrrolecarboxaldehydes, and amines.
INVENTOR(S): Jin, Qingwu; Mauragis, Michael A.; May, Paul D.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070725	A2	20030828	WO 2003-US4520	20030214
WO 2003070725	A3	20040115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002066463	A1	20020829	WO 2002-US4407	20020215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1476443	A2	20041117	EP 2003-742760	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			WO 2002-US4407	A 20020215
			US 2002-411732P	P 20020918
			US 2001-268683P	P 20010215
			US 2001-312361P	P 20010815
			WO 2003-US4520	W 20030214

OTHER SOURCE(S): CASREACT 139:214331; MARPAT 139:214331
GI

L4 ANSWER 36 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II



III

AB Title compds. [I; R1-R5 = H, alkyl, alkoxy, cycloalkyl, aryl, heterocyclyl containing 1-3 N, S, O, aryloxy, alkaryl, alkaryloxy, halo, trihalomethyl, OH, SOR', SO2NR'R'', SO3R', SR', NO2, NR'R'', CN, COR', O2CR', NHCOR', (CH2)nCO2R', CONR'R"; R6 = NR8(CH2)mR9, NR10R11, 1-2 of the CH2 groups may be substituted by OH, halo; R8 = H, alkyl; R9 = NR10R11, OH, COR12, aryl, heterocyclyl containing 1-3 N, S, O, N+(O-)R10, NHCOR13; R10, R11 = H, alkyl, cyanoalkyl, cycloalkyl, aryl, heterocyclyl containing 1-3 N, S, O; R10R11N = (R'-substituted) 5-6 membered heterocyclyl optionally containing 1-3 addnl. N, O, S; R12 = H, OH, alkoxy, aryloxy; R13 = alkyl, haloalkyl, aralkyl; R', R" = H, alkyl, cyanoalkyl, cycloalkyl, aryl, heterocyclyl containing 1-3 N, S , O; R'R"N = 5-6 membered heterocyclyl optionally containing 1-3 addnl. N, O, S; halo = F, Cl, Br, iodo; J = O, S, NH; 1 of K, L, M = CCOR6, the others of K, L, M = CR5, CR52, N, NR5, O, S; n, p = 0-2; m = 1-4], were prepared The process comprises reaction of azoles (II) with X2R (R5, J, K, L, M, p are as defined above; Q = CHO, CHS, dioxolanyl, tetrahydrooxazolyl, etc.; X1 = Cl, Br; X2 = H; R = pyrrolyl, thiazolidinethionyl, oxazolidinethionyl, imidazolidinethionyl, pyrrolidinethionyl, etc.; or X1 = OH, alkoxy, PhO; X2 = imidazolecarbonyl; R = imidazolyl) to give (III; R20 = OR, R), and reaction of III with HR6 (R6 as defined above) and the corresponding indolinone. Thus, 4-(1H-imidazol-1-ylcarbonyl)-3,5-dimethyl-1H-pyrrole-2-carboxaldehyde, N,N-diethylethylenediamine, 5-fluorooxindole, Et3N, and MeCN were mixed and heated for 18 h at 60° to give 85% N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide.
IT **326914-12-9P 356068-94-5P 452105-23-6P 452105-24-7P 452105-25-8P 452105-26-9P 557795-19-4P 587879-12-7P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing aminocarbonylpyrrolylmethylideneindolinones from

L4 ANSWER 36 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
indolinones, imidazolcarbonylpyrrolecarboxaldehydes, and amines)
RN 326914-12-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 36 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 587879-12-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 36 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-25-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-26-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 37 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:678506 CAPLUS
DOCUMENT NUMBER: 139:214337
TITLE: Preparation of 3-heteroarylmethylene-1,3-dihydro-2H-indol-2-ones as protein kinase inhibitors
INVENTOR(S): Lin, Nan-Horng; Sham, Hing L.; Xia, Ping
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003162785	A1	20030828	US 2002-317336	20021212
US 6797825	B2	20040928		
PRIORITY APPLN. INFO.:			US 2001-341410P P	20011213

OTHER SOURCE(S): MARPAT 139:214337
GI



I

AB The title compds. [I; X = N, CR3; Y = N, CR4; Z = N, CR5; with the proviso
that at least one of Y and Z is other than N; one of R3-R5 and R1 = aryl or heterocyclyl and the others are H; R2 = aryl or heterocyclyl; with the proviso that when R2 is heterocyclyl, the heterocyclyl is other than imidazolyl] which are protein kinase inhibitors, were prepared Thus, reacting 6-bromo-1,3-dihydro-2H-indol-2-one with
1H-pyrrole-2-carbaldehyde
in the presence of piperidine in MeOH followed by coupling of the resulting
(3Z)-6-bromo-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one with 4-tert-butyldimethylsilyloxy-2-methylphenylboronic acid afforded (3Z)-I [X, Y, Z = CH; R1 = 4-hydroxy-2-methylphenyl; R2 = pyrrol-2-yl]. The compds. I inhibited ChK1 at IC50 values between about 1 nM and about 10 μM.
IT **550373-92-7P 550373-93-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-heteroarylmethylene-1,3-dihydro-2H-indol-2-ones as protein
kinase inhibitors)
RN 550373-92-7 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(dimethylamino)methyl]-5-methyl-3-(1-methylethyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-hydroxy-3-methoxyphenyl)-, (3Z)- (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry as shown.



RN 550373-93-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(dimethylamino)methyl]-5-methyl-3-(1-methylethyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-hydroxy-3-methoxyphenyl)-, (3Z)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 550373-92-7
CMF C27 H31 N3 O3

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 38 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:652131 CAPLUS
DOCUMENT NUMBER: 139:214237
TITLE: Preparation of nitrate prodrugs able to release nitric
oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic
and proliferative diseases
INVENTOR(S): Scaramuzzino, Giovanni
PATENT ASSIGNEE(S): Italy
SOURCE: Eur. Pat. Appl., 313 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			EP 2002-425075	20020213

GI



II

AB New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as δ-tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thoinitrite, SNO, etc., T = OR1-M, OR1OR1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc., R1 = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OH, SH, F, Cl, Br, OPO3H2, CO2H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, O2-M2, NR2Z-M2, R1Z-M2, OR1-M2, OR1Z-M2, M2 = M, R1-M, OR1-M,

L4 ANSWER 37 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 38 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
SR1-M, NR2R1-M; ZM2 = COCH2CH(M2)CH2N+Me3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepd. For example, α-tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl deriv. II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the prepn. of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

IT **586350-09-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)

RN 586350-09-6 CAPLUS
CN L-Serine, N-[3-[5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-, nitrate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 39 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:557089 CAPLUS
DOCUMENT NUMBER: 139:390884
TITLE: SU11248 Maintenance Therapy Prevents Tumor Regrowth after Fractionated Irradiation of Murine Tumor Models
AUTHOR(S): Schueneman, Aaron J.; Himmelfarb, Eric; Geng, Ling; Tan, Jiahua; Donnelly, Edwin; Mendel, Dirk; McMahon, Gerald; Hallahan, Dennis E.
CORPORATE SOURCE: Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
SOURCE: Cancer Research (2003), 63(14), 4009-4016
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Receptor tyrosine kinase activation contributes to cell viability during cytotoxic therapy. The novel broad spectrum receptor tyrosine kinase inhibitor, SU11248, inhibits vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor, c-kit, and fetal liver tyrosine kinase 3. In this study, we maintained SU11248 plasma levels beyond the completion of radiotherapy to determine whether tumor regrowth can be delayed. The antiangiogenic effects of SU11248 were demonstrated using human umbilical vein endothelial cells in vitro. Apoptosis increased and clonogenic survival decreased when SU11248 was used in combination with radiation from 0 to 6 Gy on endothelial cells. In vivo tumor growth delay was increased in C57B6J mice with Lewis lung carcinoma or glioblastoma multiform (GL261) hind limb tumors. Mice were treated with daily i.p. injections (40 mg/kg) of SU11248 during 7 days of radiation treatment (21 Gy). Combined treatment with SU11248 and radiation significantly reduced tumor volume as compared with either treatment alone. Concomitant reduction in vasculature was confirmed using the dorsal vascular window model. The vascular length established using images taken from a consistent quadrant in the window show the combination therapy was more effective in destroying tumor vasculature than either treatment alone. SU11248 maintenance administration beyond the completion of radiotherapy results in prolongation of tumor control. In summary, SU11248 enhances radiation-induced endothelial cytotoxicity, resulting in tumor vascular destruction and tumor control when combined with fractionated radiotherapy in murine tumor models. Moreover, inhibition of angiogenesis well beyond radiation therapy may be a promising treatment paradigm for refractory human neoplasms.

IT **557795-19-4**, SU11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU11248 maintenance therapy prevents tumor regrowth after radiation)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 39 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:551511 CAPLUS
DOCUMENT NUMBER: 139:101028
TITLE: Preparation of pyrrolylmethyleneindolones as protein kinase inhibitors and antitumor agents
INVENTOR(S): Griffin, John H.; Briesewitz, Roger; Wray, Jonathan W.
PATENT ASSIGNEE(S): Theravance, Inc., USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057690	A1	20030717	WO 2002-US41252	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003171378	A1	20030911	US 2002-327385	20021220
US 6686362	B2	20040203		
EP 1458713	A1	20040922	EP 2002-796035	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015360	A	20041214	BR 2002-15360	20021220
US 2004198804	A1	20041007	US 2003-691094	20031022

PRIORITY APPLN. INFO.: US 2001-343746P P 20011227
US 2001-343813P P 20011227
US 2002-327385 A3 20021220
WO 2002-US41252 W 20021220

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = H, alkyl; R2 = -A1-NR5R6; R5, R6 = independently H, alkyl; A1 = (CH2)m, (CH2)n-A2-(CH2)p, (CH2CH2O)qCH2CH2; m = 2-10; n, p = 1-6; A2 = CH=CH, phenylene, biphenylene, cyclohexylene, piperazinylene; q = 1-3; or NR1R2 = morpholinyl, (un)substituted azirinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, azacrown ethers, etc.; R3, R4 = H, halo, alkyl, alkoxy, un(substituted) Ph, SO2NH2 or alkyl/aryl derivs., certain acylamino; and their pharmaceutically acceptable salts] were prepared as receptor tyrosine kinase inhibitors useful in the treatment of proliferative disorders, such as cancer. For example, compd. II•(F3CCO2H)x was prepd. from 3,5-dimethyl-2,4-pyrrole dicarboxylic acid di-Et ester in 11 steps via condensation with malonic acid, condensation with oxindole, amidation with mono-Boc piperazine and Boc deprotection using TFA. I exhibit an IC50 values of < 10 μM for inhibition of Flt-3, VEGFR and PDGFR tyrosinase kinases. II inhibited mutant Flt-3 tyrosinase kinase with EC50 = 0.24 μM.

IT **560071-97-8P 560071-99-0P 560072-01-7P**
560072-04-0P 560072-07-3P 560072-10-8P
560072-13-1P 560072-16-4P 560072-19-7P
560072-22-2P 560072-25-5P 560072-28-8P
560072-31-3P 560072-34-6P 560072-37-9P
560072-40-4P 560072-43-7P 560072-46-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tyrosine kinase inhibitor; preparation of pyrrolylmethylenedihydroindolones as protein kinase inhibitors and antitumor agents)
RN 560071-97-8 CAPLUS
CN 1H-Pyrrole-3-propanamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-N-[2-(methylamino)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 560071-96-7
CMF C22 H28 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560071-99-0 CAPLUS
CN 1H-Pyrrole-3-propanamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-N-[3-(methylamino)propyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 1

CRN 560071-98-9
CMF C23 H30 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-01-7 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[4-(methylamino)butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-00-6
CMF C24 H32 N4 O2



CM 2

CRN 76-05-1

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CMF C2 H F3 O2

RN 560072-04-0 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[5-(methylamino)pentyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-03-9
CMF C25 H34 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-07-3 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[6-(methylamino)hexyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-06-2
CMF C26 H36 N4 O2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-10-8 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[7-(methylamino)heptyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-09-5
CMF C27 H38 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 560072-13-1 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[8-(methylamino)octyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-12-0
CMF C28 H40 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-16-4 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[9-(methylamino)nonyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-15-3
CMF C29 H42 N4 O2



CM 2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-19-7 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[10-(methylamino)decyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-18-6
CMF C30 H44 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-22-2 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[2-(methylamino)dodecyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 560072-28-8 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[2-[2-[2-(methylamino)ethoxy]ethoxy]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-27-7
CMF C26 H36 N4 O4

PAGE 1-A



PAGE 1-B

—CH2—NHMe

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-31-3 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CRN 560072-21-1
CMF C32 H48 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-25-5 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[4-(methylamino)-2-butenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-24-4
CMF C24 H30 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
N-[2-[2-(2-ethoxyethoxy)ethoxy]-1-(methylamino)ethyl]-N,2,4-trimethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-30-2
CMF C28 H40 N4 O5

PAGE 1-A



PAGE 1-B

—CH2—OEt

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-34-6 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[[3-[(methylamino)methyl]phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-33-5
CMF C28 H32 N4 O2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-37-9 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[[4-[(methylamino)methyl]phenyl]methyl]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-36-8
CMF C28 H32 N4 O2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-40-4 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[[3-[(methylamino)methyl]cyclohexyl]methyl]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-39-1
CMF C28 H38 N4 O2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-43-7 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-

N,2,4-trimethyl-N-[[2'-[(methylamino)methyl][1,1'-biphenyl]-2-yl]methyl]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-42-6
CMF C34 H36 N4 O2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 560072-46-0 CAPLUS
CN 1H-Pyrrole-3-propanamide,
5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N,2,4-trimethyl-N-[3-[4-[3-(methylamino)propyl]-1-piperazinyl]propyl]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 560072-45-9
CMF C30 H44 N6 O2

L4 ANSWER 40 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 41 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:534741 CAPLUS
DOCUMENT NUMBER: 139:214284
TITLE: Early Amidation Approach to 3-[(4-Amido)pyrrol-2-yl]-2-indolinones
AUTHOR(S): Manley, Jerad M.; Kalman, Monica J.; Conway, Brian G.; Ball, Cynthia C.; Havens, Jeffrey L.; Vaidyanathan, Rajappa
CORPORATE SOURCE: Chemical Research and Development, Pfizer Inc., Kalamazoo, MI, 49001, USA
SOURCE: Journal of Organic Chemistry (2003), 68(16), 6447-6450
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:214284

AB A new synthesis of 3-[(4-amido)pyrrol-2-yl]-2-indolinones has been developed, where the amide side chain was installed prior to pyrrole formation. This strategy precludes the need to use any coupling reagents to install the amide side chain. This process includes a zinc-free alternative to the Knorr pyrrole synthesis.

IT **557795-19-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 3-[(4-amido)pyrrol-2-yl]-2-indolinones via an early amidation approach)

RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 42 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:532545 CAPLUS
DOCUMENT NUMBER: 139:95455
TITLE: Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
INVENTOR(S): Geroni, Maria Cristina; Fowst, Camilla; Cozzi, Paolo
PATENT ASSIGNEE(S): Pharmacia Italia SpA, Italy
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055522	A1	20030710	WO 2002-EP13092	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1461083	A1	20040929	EP 2002-787763	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015454	A	20041123	BR 2002-15454	20021218
PRIORITY APPLN. INFO.:			EP 2002-75052 A	20020102
			WO 2002-EP13092 W	20021218

OTHER SOURCE(S): MARPAT 139:95455
GI

L4 ANSWER 42 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The present invention provides the combined use of acryloyl distamycin derivs., in particular α-bromo- and α-chloro-acryloyl distamycin derivs., and a protein kinase (serine/threonine and tyrosine kinases) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis. An example protein kinase inhibitor is STI 571 and a distamycin derivative is brostallicin (I).

IT **557795-19-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined antitumor therapy comprising acryloyl distamycin derivs. and protein kinase (serine/threonine kinase) inhibitors)

RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 42 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 43 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
NAME)

Double bond geometry as shown.



REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:528824 CAPLUS
DOCUMENT NUMBER: 140:70428
TITLE: Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies
AUTHOR(S): London, Cheryl A.; Hannah, Alison L.; Zadovoskaya, Regina; Chien, May B.; Kollias-Baker, Cynthia; Rosenberg, Mona; Downing, Sue; Post, Gerald; Boucher, Joseph; Shenoy, Narmada; Mendel, Dirk B.; McMahon, Gerald; Cherrington, Julie M.
CORPORATE SOURCE: School of Veterinary Medicine, University of California, Davis, CA, 95616, USA
SOURCE: Clinical Cancer Research (2003), 9(7), 2755-2768
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The purpose of the following study was to investigate the safety and efficacy of the novel multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor, SU11654, using a canine model of spontaneous tumors. This p.o. bioavailable compound exhibits potent inhibitory activity against members of the split kinase family of RTKs, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor, Kit, and Flt-3, resulting in both direct antitumor and antiangiogenic activity. This was a Phase I trial in which successive cohorts of dogs with spontaneous tumors that had failed standard treatment regimens received escalating doses of SU11654 as oral therapy. Pharmacokinetics, toxicity, and tumor response were assessed. Fifty-seven dogs with a variety of cancers were enrolled; of these, 10 experienced progressive disease within the first 3 wk. Measurable objective responses were observed in 16 dogs (including 6 complete responses), primarily in mast cell tumors (n = 11), mixed mammary carcinomas (n = 2), soft tissue sarcomas (n = 2), and multiple myeloma (n = 1), for an overall response rate of 28% (16 of 57). Stable disease of sufficient duration to be considered clin. meaningful (>10 wk) was seen in an addnl. 15 dogs, for a resultant overall biol. activity of 54% (31 of 57). This study provides the first evidence that p.o. administered kinase inhibitors can exhibit activity against a variety of spontaneous malignancies. Given the similarities of canine and human cancers with regard to tumor biol. and the presence of analogous RTK dysregulation, it is likely that such agents will demonstrate comparable antineoplastic activity in people.
IT **356068-94-5**, SU11654
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small mol. receptor tyrosine kinase inhibitor SU11654 in dogs with spontaneous malignancies)
RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX

L4 ANSWER 44 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:491184 CAPLUS
DOCUMENT NUMBER: 139:69154
TITLE: Preparation of 3-heteroarylmethylene-1,3-dihydro-2H-indol-2-ones as protein kinase inhibitors
INVENTOR(S): Lin, Nan-Horng; Sham, Hing L.; Xia, Ping
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051838	A2	20030626	WO 2002-US39641	20021212
WO 2003051838	A3	20030918		
W: CA, JP, MX				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
US 2003119839	A1	20030626	US 2001-22290	20011213
EP 1453800	A2	20040908	EP 2002-790089	20021212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-22290	A 20011213
			WO 2002-US39641	W 20021212

OTHER SOURCE(S): MARPAT 139:69154
GI



I

AB The title compds. [I; X = N, CR3; Y = N, CR4; Z = N, CR5; with the proviso that at least one of Y and Z is other than N; one of R3-R5 and R1 = aryl or heterocyclyl and the others are H; R2 = aryl or heterocyclyl; with the proviso that when R2 is heterocyclyl, the heterocyclyl is other than imidazolyl] which are protein kinase inhibitors, were prepared Thus, reacting 6-bromo-1,3-dihydro-2H-indol-2-one with 1H-pyrrole-2-carbaldehyde in the presence of piperidine in MeOH followed by coupling of the resulting (3Z)-6-bromo-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one with 4-tert-butyldimethylsilyloxy-2-methylphenylboronic acid afforded (3Z)-I [X, Y, Z = CH; R1 = 4-hydroxy-2-methylphenyl; R2 = pyrrol-2-yl]. The compds. I inhibited ChK1 at IC50 values between about 1 nM and about 10 μM.
IT **550373-92-7P 550373-93-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L4 ANSWER 44 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(Uses)
(prepn. of 3-heteroarylmethylene-1,3-dihydro-2H-indol-2-ones as protein
kinase inhibitors)
RN 550373-92-7 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(dimethylamino)methyl]-5-methyl-3-(1-methylethyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-hydroxy-3-methoxyphenyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 550373-93-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(dimethylamino)methyl]-5-methyl-3-(1-methylethyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-hydroxy-3-methoxyphenyl)-, (3Z)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 550373-92-7
CMF C27 H31 N3 O3

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 44 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 45 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:483832 CAPLUS
DOCUMENT NUMBER: 139:207284
TITLE: SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer
AUTHOR(S): Abrams, Tinya J.; Lee, Leslie B.; Murray, Lesley J.; Pryer, Nancy K.; Cherrington, Julie M.
CORPORATE SOURCE: Preclinical Research and Exploratory Development, Sugen, Inc., South San Francisco, CA, 94080, USA
SOURCE: Molecular Cancer Therapeutics (2003), 2(5), 471-478
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine kinase KIT in vitro and in vivo, examine the role of KIT in small cell lung cancer (SCLC), and anticipate clin. utility of SU11248 in SCLC. SU11248 is an oral, multitargeted tyrosine kinase inhibitor with direct antitumor and antiangiogenic activity through targeting platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor, KIT, and FLT3 receptors. Treatment of the KIT-expressing SCLC-derived NCI-H526 cell line in vitro with SU11248 resulted in dose-dependent inhibition of stem cell factor-stimulated KIT phosphotyrosine levels and proliferation. The biol. significance of KIT inhibition was evaluated in vivo by treating mice bearing s.c. NCI-H526 tumors with SU11248 or another structurally unrelated KIT inhibitor, STI571 (Gleevec), which is also known to inhibit Bcr-Abl and PDGFRβ. SU11248 treatment resulted in significant tumor growth inhibition, whereas inhibition from STI571 treatment was less dramatic. Both compds. reduced phospho-KIT levels in NCI-H526 tumors, with a greater reduction by SU11248, correlating with efficacy. Likewise, phospho-PDGFRβ levels contributed by tumor stroma and with known involvement in angiogenesis were strongly inhibited by SU11248 and less so by STI571. Because platinum-based chemotherapy is part of the standard of care for SCLC, SU11248 was combined with cisplatin, and significant tumor growth delay was measured compared with either agent alone. These results expand the profile of SU11248 as a KIT signaling inhibitor and suggest that SU11248 may have clin. potential in the treatment of SCLC via direct antitumor activity mediated via KIT as well as tumor angiogenesis via vascular endothelial growth factor receptor FLK1/KDR and PDGFRβ.
IT 557795-19-4, SU11248
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclin. models of human small cell lung cancer)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 45 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:362945 CAPLUS
DOCUMENT NUMBER: 139:173373
TITLE: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AUTHOR(S): O'Farrell, Anne-Marie; Abrams, Tinya J.; Yuen, Helene A.; Ngai, Theresa J.; Louie, Sharianne G.; Yee, Kevin W. H.; Wong, Lily M.; Hong, Weiru; Lee, Leslie B.; Town, Ajia; Smolich, Beverly D.; Manning, William C.; Murray, Lesley J.; Heinrich, Michael C.; Cherrington, Julie M.
CORPORATE SOURCE: Preclinical Research and Exploratory Development, SUGEN, South San Francisco, CA, 94080, USA
SOURCE: Blood (2003), 101(9), 3597-3605
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells. In blasts from acute myelogenous leukemia (AML) patients, 2 classes of FLT3 activating mutations have been identified: internal tandem duplication (ITD) mutations in the juxtamembrane domain (25%-30% of patients) and point mutations in the kinase domain activation loop (7%-8% of patients). FLT3-ITD mutations are the most common mol. defect identified in AML and have been shown to be an independent prognostic factor for decreased survival. FLT3-ITD is therefore an attractive mol. target for therapy. SU11248 is a recently described selective inhibitor with selectivity for split kinase domain RTKs, including platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and KIT. We show that SU11248 also has potent activity against wild-type FLT3 (FLT3-WT), FLT3-ITD, and FLT3 activation loop (FLT3-Asp835) mutants in phosphorylation assays. SU11248 inhibits FLT3-driven phosphorylation and induces apoptosis in vitro. In addition, SU11248 inhibits FLT3-induced VEGF production The in vivo efficacy of SU11248 was investigated in 2 FLT3-ITD models: a s.c. tumor xenograft model and a bone marrow engraftment model. We show that SU11248 (20 mg/kg/d) dramatically regresses FLT3-ITD tumors in the s.c. tumor xenograft model and prolongs survival in the bone marrow engraftment model. Pharmacokinetic and pharmacodynamic anal. in s.c. tumors showed that a single administration of an efficacious drug dose potently inhibits FLT3-ITD phosphorylation for up to 16 h following a single dose. These results suggest that further exploration of SU11248 activity in AML patients is warranted.

IT **557795-19-4**, SU11248
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FLT3 tyrosine kinase inhibitor SU11248 induces acute myelogenous leukemia apoptosis)

RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 46 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:334853 CAPLUS
DOCUMENT NUMBER: 138:331677
TITLE: Treatment of acute myeloid leukemia with indolinone compounds, and preparation thereof
INVENTOR(S): O'Farrell, Ann-Marie; Cherrington, Julie
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035009	A2	20030501	WO 2002-US34525	20021028
WO 2003035009	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003130280	A1	20030710	US 2002-281266	20021028
EP 1446117	A2	20040818	EP 2002-795563	20021028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013960	A	20040831	BR 2002-13960	20021028
PRIORITY APPLN. INFO.:			US 2001-330623P P	20011026
			WO 2002-US34525 W	20021028

OTHER SOURCE(S): MARPAT 138:331677
GI



I

AB A method of treating acute myeloid leukemia in patient pos. for FLT-3-ITD is described. The treatment is accomplished by administration of an indolinone compound (Markush included). Preparation of the compds. of the

L4 ANSWER 47 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
invention, e.g. I, is described.

IT **342641-94-5P 346405-32-1P 356068-97-8P**
452104-85-7P 452104-87-9P 452105-23-6P
452105-24-7P 515138-82-6P 557795-19-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(indolinone derivative preparation for treatment of acute myeloid leukemia)

RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 47 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-85-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-87-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 47 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **499220-14-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(indolinone derivative preparation for treatment of acute myeloid leukemia)
RN 499220-14-3 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5
CMF C22 H27 F N4 O2



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



L4 ANSWER 47 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 515138-82-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 47 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT **452104-42-6P 452104-86-8P 452104-88-0P**
452104-89-1P 452104-90-4P 452104-91-5P
452104-92-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(indolinone derivative preparation for treatment of acute myeloid leukemia)
RN 452104-42-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-86-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-88-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-89-1 CAPLUS

L4 ANSWER 47 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-90-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-91-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-92-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 47 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 48 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:239162 CAPLUS
DOCUMENT NUMBER: 139:331991
TITLE: VEGF blocking therapy in the treatment of cancer
AUTHOR(S): Glade-Bender, Julia; Kandel, Jessica J.; Yamashiro, Darrell J.
CORPORATE SOURCE: Divisions of Pediatric Oncology and Pediatric Surgery, College of Physicians and Surgeons at Columbia University, New York, NY, 10032, USA
SOURCE: Expert Opinion on Biological Therapy (2003), 3(2), 263-276
CODEN: EOBTA2; ISSN: 1471-2598
PUBLISHER: Ashley Publications Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. It is widely accepted that tumor growth beyond a few cubic millimeters cannot occur without the induction of a new vascular supply. Inhibiting the development of new blood vessels (antiangiogenesis) is a potential approach to cancer therapy that has attracted interest in recent years. In theory, this approach should be relatively selective for tumor cells. The endothelial cells which form new vascular networks in tumors are responding to angiogenic stimuli produced by the tumor, but are themselves genetically normal. Endothelium in normal tissue, by contrast, is usually quiescent. Vascular endothelial growth factor (VEGF) is the best-characterized pro-angiogenic factor. It is virtually ubiquitous in human tumors, and higher levels have been correlated with more aggressive disease. Effective blockade of the VEGF pathway has been demonstrated with multiple agents: neutralizing antibody, receptor tyrosine kinase inhibitors, and ribozyme or antisense mols. targeting expression. Promising preclin. data document the potential of these agents for tumor growth inhibition and even tumor regression, yet translation of novel therapeutics targeting the VEGF pathway to the clinic has proved a substantial challenge in itself. While showing clear evidence of antitumor activity over a broad spectrum of exptl. tumors, the proper selection, dose, timing and sequence of anti-VEGF treatment in human cancer is not at all obvious. Classic Phase I dose escalation trial design may need to be modified, as higher doses may not be optimal in all patients or for all tumors. In addition, alternate or secondary biol. end points (e.g., non-progression) may be needed for early phase studies to document true activity, so as not to abandon effective agents. Recent studies of the neutralizing antibody bevacizumab, and small mol. tyrosine kinase inhibitor SU5416, demonstrate that, while unlikely to be effective as monotherapy, incorporation of VEGF blockade into cytotoxic regimens may increase overall response rates. However, incorporation may also produce new toxicities, including thromboembolic complications and bleeding. Newer oral agents, such as SU6668, SU11248, PTK787/ZK222584 and ZD6474, are particularly interesting for their potential for chronic therapy. Future clin. trials are likely to build on past experience with stricter entry criteria, supportive care guidelines and the use of surrogate markers.

IT 557795-19-4, SU11248
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VEGF blocking therapy in treatment of cancer in relation to angiogenesis inhibition)

L4 ANSWER 48 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 166 THERE ARE 166 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 49 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:170636 CAPLUS
DOCUMENT NUMBER: 138:337929
TITLE: Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase
AUTHOR(S): Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho
CORPORATE SOURCE: SUGEN Inc., South San Francisco, CA, 94080, USA
SOURCE: Journal of Medicinal Chemistry (2003), 46(7), 1116-1119
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:337929
GI



I

AB To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized. Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, solubility, protein binding, and bioavailability. II is currently in phase I clin. trials for the treatment of cancers.

IT **342641-63-8P 342641-94-5P 346405-32-1P 356068-90-1P 356068-91-2P 356068-96-7P 515138-81-5P 515138-82-6P 515138-83-7P 515138-84-8P**

L4 ANSWER 49 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-90-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 49 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of (pyrrolylmethylidene)indolinones as tyrosine kinase inhibitors targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase)

RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 49 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 515138-81-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 515138-82-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 49 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 515138-83-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 515138-84-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 49 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 50 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:154425 CAPLUS
DOCUMENT NUMBER: 138:193304
TITLE: Preparation of crystals of a malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
INVENTOR(S): Hawley, Michael; Fleck, Thomas J.; Prescott, Stephen P.; Maloney, Mark T.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016305	A1	20030227	WO 2002-US25649	20020813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003069298	A1	20030410	US 2002-218985	20020813
EP 1419151	A1	20040519	EP 2002-759342	20020813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011612	A	20040824	BR 2002-11612	20020813
NZ 531232	A	20041126	NZ 2002-531232	20020813
JP 2005503386	T2	20050203	JP 2003-521228	20020813
PRIORITY APPLN. INFO.:			US 2001-312353P P	20010815
			WO 2002-US25649 W	20020813

AB The present invention provides crystals, and compns. of the title compound
Methods of preparing such crystals are also disclosed. Thus, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide. was dissolved in MeOH and L-malic acid wass added to the solution The MeOh was removed and MeCN was added and
the slurry was stirred and heated for 10 min. After cooling, the crystal form I of the title compound was obtained.
IT **499220-14-3P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystals of malic acid salt of (diethylamino)ethyl(fluorooxo indolyidene)methyldimethylpyrrolecarboxamide)
RN 499220-14-3 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5
CMF C22 H27 F N4 O2



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



IT **342641-94-5**
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of crystals of malic acid salt of (diethylamino)ethyl(fluorooxo indolyidene)methyldimethylpyrrolecarboxamide)
RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 50 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:154170 CAPLUS
DOCUMENT NUMBER: 138:180703
TITLE: Combination therapy for the treatment of cancer
INVENTOR(S): Doshi, Parul; Cherrington, Julie
PATENT ASSIGNEE(S): Masferrer, Jaime, USA; Sugen Inc.
SOURCE: PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015608	A2	20030227	WO 2002-US25797	20020815
WO 2003015608	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003216410	A1	20031120	US 2002-218910	20020815
BR 2002011978	A	20040720	BR 2002-11978	20020815
JP 2005501843	T2	20050120	JP 2003-520373	20020815
PRIORITY APPLN. INFO.:			US 2001-312413P	P 20010815
			WO 2002-US25797	W 20020815

OTHER SOURCE(S): MARPAT 138:180703
GI



I

AB The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
selective inhibitors. The protein kinase inhibitors are of the formula I where R = H, piperazin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, piperidin-1-ylmethyl, etc.; R1 = H, halo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, etc.; R2 = hydrogen, halo, alkyl, substituted alkyl, trihalomethyl, hydroxy, alkoxy, etc.; R3 = H, halogen, alkyl, substituted alkyl, trihalomethyl, hydroxy, alkoxy, aryl, heteroaryl, etc.; R4 = H, halogen, alkyl, substituted alkyl, hydroxy, alkoxy, etc.; R5 = H, alkyl, substituted alkyl, etc.; R6 = hydrogen, alkyl, substituted alkyl, etc.; and R7 = H, alkyl, substituted alkyl, aryl, heteroaryl, etc.

IT **356068-97-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(combination therapy for treatment of cancer using protein tyrosine kinase inhibitors and cyclooxygenase-2 inhibitors)

RN 356068-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **342641-49-0P 342641-50-3P 342641-51-4P**
342641-52-5P 342641-54-7P 342641-55-8P
342641-56-9P 342641-57-0P 342641-59-2P
342641-60-5P 342641-61-6P 342641-62-7P
342641-63-8P 342641-64-9P 342641-65-0P
342641-66-1P 342641-67-2P 342641-68-3P
342641-69-4P 342641-70-7P 342641-71-8P
342641-72-9P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide **342641-73-0P**, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide **342641-74-1P**, 5-[6-(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-75-2P**, 2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-76-3P**
342641-77-4P, 2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide **342641-78-5P**, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide **342641-79-6P**, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-80-9P**, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-81-0P**, 3-[4-(3-Diethylaminopropylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)amide **342641-82-1P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-83-2P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-84-3P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-85-4P 342641-87-6P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)-amide **342641-88-7P 342641-89-8P**,

5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide **342641-91-2P 342641-92-3P**, 5-[6-(2,4-Dimethoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide **342641-93-4P**, 5-[6-(3-Isopropylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide **342641-95-6P**, 3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid **342641-96-7P**, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide **342641-97-8P 342641-98-9P**
, 2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide **342642-01-7P**, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342642-02-8P**, 5-[5-(3-Chlorophenyl sulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342642-10-8P**
342642-11-9P 356068-82-1P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2.4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide **356068-90-1P 356068-91-2P**
, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide **356068-92-3P**, 2.4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ethyl)amide **356068-95-6P**, 2.4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide **356068-96-7P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide **356068-99-0P**, 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoaminoethyl)-amide **356069-03-9P**
356069-04-0P 356069-05-1P 356069-07-3P
356069-09-5P, 5-[2-Oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(3,5-dimethylpiperazin-1-yl)ethyl)amide **356069-12-0P 356069-13-1P**, 5-[5-Chloro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(3,5-dimethylpiperazin-1-yl)ethyl)amide **356069-15-3P**, 5-[5-Bromo-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(3,5-dimethylpiperazin-1-yl)ethyl)amide **356069-24-4P**
356069-25-5P 356069-26-6P 356069-36-8P
356069-37-9P 356069-38-0P 356069-39-1P
356069-40-4P 356069-41-5P 356069-42-6P
356069-43-7P 356069-44-8P 356069-45-9P

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
356069-46-0P 356069-47-1P 356069-48-2P
356069-49-3P 356069-50-6P 356069-51-7P
356069-53-9P 356069-55-1P 356069-57-3P
356069-58-4P 356069-59-5P 356069-60-8P
356069-61-9P 356069-62-0P 356069-64-2P
356069-65-3P 356069-66-4P 356069-77-7P
557795-19-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination therapy for treatment of cancer using protein tyrosine kinase inhibitors and cyclooxygenase-2 inhibitors)
RN 342641-49-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-50-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 342641-51-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-N-[2-(diethylamino)ethyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-54-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-57-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-66-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-68-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-71-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-72-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-73-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-74-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-75-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-76-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-77-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-78-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 342641-79-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-
5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-80-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-
6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-81-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-
(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-
yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX
NAME)



RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI)
(CA INDEX NAME)



RN 342641-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(CA INDEX NAME)



RN 342641-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]-
(9CI)
(CA INDEX NAME)



RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX
NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-88-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)



RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-
methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-
pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-95-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342642-01-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-10-8 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-11-9 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-90-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 356068-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-95-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-99-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-03-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-04-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-05-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 356069-09-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 356069-13-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-07-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry as shown.



RN 356069-15-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-24-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-25-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-26-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-36-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-37-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-38-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-39-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-40-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-41-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-42-6 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-43-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-44-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-48-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-49-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-50-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-45-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(cyanomethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-46-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-47-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-51-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-53-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-52-8
CMF C22 H24 F N5 O3

Double bond geometry as shown.



CM 2

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2

RN 356069-55-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-54-0
CMF C22 H25 N5 O3

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 356069-57-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-56-2
CMF C23 H24 N6 O3

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 356069-58-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-59-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-60-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-61-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-62-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-64-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-63-1
CMF C22 H24 Cl N5 O3

Double bond geometry as shown.



CM 2

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2

RN 356069-65-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-66-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-77-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **342641-94-5 346405-32-1 356069-16-4 356069-17-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy for treatment of cancer using protein tyrosine kinase inhibitors and cyclooxygenase-2 inhibitors)

RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-16-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-17-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **342642-09-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(combination therapy for treatment of cancer using protein tyrosine

L4 ANSWER 51 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
kinase inhibitors and cyclooxygenase-2 inhibitors)
RN 342642-09-5 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **356068-94-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(combination therapy for treatment of cancer using protein tyrosine kinase inhibitors and cyclooxygenase-2 inhibitors)
RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 52 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
in human trials.
IT **557795-19-4**, SU11248
RL: DMA (Drug mechanism of action); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship)
RN 557795-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:72786 CAPLUS
DOCUMENT NUMBER: 139:239801
TITLE: In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship
AUTHOR(S): Mendel, Dirk B.; Laird, A. Douglas; Xin, Xiaohua; Louie, Sharianne G.; Christensen, James G.; Li, Guangmin; Schreck, Randall E.; Abrams, Tinya J.; Ngai, Theresa J.; Lee, Leslie B.; Murray, Lesley J.; Carver, Jeremy; Chan, Emily; Moss, Katherine G.; Haznedar, Joshua O.; Sukbuntherng, Juthamas; Blake, Robert A.; Sun, Li; Tang, Cho; Miller, Todd; Shirazian, Sheri; McMahon, Gerald; Cherrington, Julie M.
CORPORATE SOURCE: Preclinical Research and Exploratory Development, SUGEN, Inc., South San Francisco, CA, 94080, USA
SOURCE: Clinical Cancer Research (2003), 9(1), 327-337
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB One challenging aspect in the clin. development of molecularly targeted therapies, which represent a new and promising approach to treating cancers, has been the identification of a biol. active dose rather than a maximum tolerated dose. The goal of the present study was to identify a pharmacokinetic/pharmacodynamic relationship in preclin. models that could be used to help guide selection of a clin. dose. SU11248, a novel small mol. receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity via targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, was used as the pharmacol. agent in these studies. In mouse xenograft models, SU11248 exhibited broad and potent antitumor activity causing regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines. To predict the target SU11248 exposure required to achieve antitumor activity in mouse xenograft models, we directly measured target phosphorylation in tumor xenografts before and after SU11248 treatment and correlated this with plasma inhibitor levels. In target modulation studies in vivo, SU11248 selectively inhibited Flk-1/KDR (VEGF receptor 2) and PDGF receptor β phosphorylation (in a time- and dose-dependent manner) when plasma concns. of inhibitor reached or exceeded 50-100 ng/mL. Similar results were obtained in a functional assay of VEGF-induced vascular permeability in vivo. Constant inhibition of VEGFR2 and PDGF receptor β phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 h of a 24-h dosing interval. The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclin. studies has aided in the design, selection, and evaluation of dosing regimens being tested

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:927188 CAPLUS
DOCUMENT NUMBER: 138:14005
TITLE: Preparation of 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
INVENTOR(S): Cui, Jingrong; Ramphal, Yudhi; Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 479 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096361	A2	20021205	WO 2002-US16841	20020530
WO 2002096361	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003125370	A1	20030703	US 2002-157007	20020530
US 6599902	B2	20030729		

PRIORITY APPLN. INFO.: US 2001-294544P P 20010530
US 2001-328408P P 20011010

OTHER SOURCE(S): MARPAT 138:14005
GI



I

AB The present invention relates to certain 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. (shown as I; see below for variable definitions; e.g. 2,4-dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dihydroindol-(3Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide) that inhibit kinases (no data), in particular met kinase. Pharmaceutical compns. comprising these compds., methods of treating diseases mediated by kinases using pharmaceutical compns. comprising these compds., and methods of prepg. them are also disclosed. In I: n = 0-2; m = 1-3; R1 and R2 = H or alkyl; R3, R4, and R5 = H, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, alkoxycarbonyl, haloalkoxy, cyano, carboxy, carboxyalkyl, nitro, aryl, aryloxy, heteroaryl, heteroaryloxy, -(alkylene)-CONR10R11, -CONR10R11, or - NR10R11 (R10 is H or alkyl, and R11 is aryl, heteroaryl, heterocycle, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, aralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy, or R10 and R11 together with the N atom to which they are attached combine to form satd. or unsatd. heterocycloamino). R6 is H, alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, heterocyclylalkyl, aryl, heteroaryl, carboxy, alkoxycarbonyl, heterocyclylcarbonyl, aminoalkylcarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, -CONR10R11 or -(alkylene)-CONR10R11. R7 and R8 = H, alkyl, cycloalkyl, heterocyclylalkyl, -COR12, -(alkylene)-COR12 (R12 = alkoxy, hydroxy, or heterocycle, alkylamino, dialkylamino), -SO2R14, -CONR13R14, or -(alkylene)-CONR13R14 (R13 is H or alkyl, and R14 is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s), or when R13 and R14 are attached to a N atom R13 and R14 together with the N atom to which they are attached form satd. or unsatd. heterocycloamino). R6 and R7 or R7 and R8 can combine to form a satd. or unsatd. 5 to 8 membered ring; and R9 is: H or alkyl; -PO(OR15)2 where each R15 = H or alkyl; -COR16 where R16 is H or alkyl; or -CHR17NR18R19 where R17 is H or alkyl, and R18 and R19 = H or alkyl or R18 and R19 together with the N atom to which they are attached form heterocycloamino. Although the methods of prepn. are not claimed, 375 example prepns. of I plus addnl. prepns. of intermediates are included.

IT **477576-36-6P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-(piperazin-1-yl)ethyl)acetamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)

RN 477576-36-6 CAPLUS

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **477573-60-7P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-61-8P**, 5-[5-(2-Cyanophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-62-9P**, 2,4-Dimethyl-5-[2-oxo-5-(3-trifluoromethylphenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-63-0P**, 5-[5-(3-Methoxyphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-67-4P**,

2,4-Dimethyl-5-[5-(2-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-68-5P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-[1,2,3]triazol-1-ylethyl)amide **477573-69-6P**,

2,4-Dimethyl-5-[5-(2-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-[1,2,3]triazol-1-ylethyl)amide **477573-74-3P**, 4-[[[3-[1-[4-(2-

Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]benzoic acid **477573-75-4P**, [4-[[[3-[1-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]phenyl]acetic acid **477573-76-5P**, 4-[[[3-[1-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]-3-nitrobenzoic acid **477573-78-7P**, 5-[5-(3,5-Dibromo-2-

hydroxyphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-79-8P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[1,2,3]triazol-1-ylethyl)amide **477573-80-1P**,

2,4-Dimethyl-5-(4-methyl-2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-81-2P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-4-methyl-2-oxo-

1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-82-3P**, 5-[5-(2-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-83-4P**, 4-[[[3-[1-[4-(2-

Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]benzoic acid methyl ester **477573-84-5P**, 5-[5-(4-Trifluoromethoxyphenylmethanesulfonyl)-2-oxo-

1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-86-7P**, 5-[5-[2,4-Bis(trifluoromethyl)phenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-88-9P**, 5-[5-(4-Bromophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-89-0P**, 5-[5-(2-

Iodophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-91-4P**, 5-[5-(4-Cyanophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-93-6P**, 3-[[[3-[1-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]benzoic acid methyl ester **477573-96-9P**, 2,4-Dimethyl-5-[2-oxo-5-(3-trifluoromethoxyphenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-98-1P**, 5-[5-(3-Cyanophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-00-8P**, 2,4-Dimethyl-5-(2-oxo-5-m-tolylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-02-0P**, 5-[5-(2,4-

Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-04-2P**, 5-[5-(4-tert-Butylphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-06-4P**, 5-[5-(2,6-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-08-6P**, 5-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-11-1P**, 2,4-Dimethyl-5-[5-(4-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-13-3P**, 2,4-Dimethyl-5-[5-(3-

nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-14-4P**, 5-[5-(3-Bromophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-16-6P**, 5-[5-(3,5-

Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-18-8P**, 5-[5-(3,4-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-20-2P**, 5-[5-[2,5-Bis(trifluoromethyl)phenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-22-4P**, 5-[5-[3,5-Bis(trifluoromethyl)phenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-24-6P**,

5-[5-(2-Hydroxy-5-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-26-8P**, 5-[5-(2-Methoxy-5-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-28-0P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-30-4P**, 5-[5-(3-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-32-6P**, 5-[5-(4-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-35-9P**, 2,4-Dimethyl-5-(2-oxo-5-(2-trifluoromethylphenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-37-1P**, 2,4-Dimethyl-5-[2-oxo-5-(4-trifluoromethylphenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-40-6P**, 2,4-Dimethyl-5-(2-oxo-5-

pentafluorophenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-42-8P**, 5-[5-(2,5-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-44-0P**, 2,4-Dimethyl-5-(2-oxo-5-(2,3,6-trifluorophenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-46-2P**, 5-[5-(2,3-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-47-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-49-5P**, 5-[5-(Biphenyl-2-ylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-51-9P**, 5-[5-(2-Fluoro-6-nitrophenylmethanesulfonyl)-2-oxo-

1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-53-1P**, 5-[5-[2-(2-Fluorophenoxy)phenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(2-diethylaminoethyl)amide **477574-55-3P**, 5-[5-(4-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-59-7P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylamino-2-hydroxypropyl)amide **477574-60-0P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid [2-(2H-tetrazol-5-yl)ethyl]amide **477574-64-4P**, 4-Methyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-65-5P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **477574-66-6P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diisopropylaminoethyl)amide **477574-67-7P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **477574-68-8P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-70-2P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diisopropylaminoethyl)amide **477574-74-6P**, 5-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-77-9P**, 5-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **477574-78-0P**, 5-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diisopropylaminoethyl)amide **477574-88-2P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(morpholin-4-yl)propyl)amide **477574-89-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-[1,2,3]triazol-1-ylpropyl)amide **477574-90-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3-oxopiperazin-1-yl)ethyl]amide **477575-11-4P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxyethyl)amide **477575-16-9P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid methyl(1-methylpiperidin-4-yl)amide **477575-22-7P**, 2-[5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(3-oxopiperazin-1-yl)ethyl]acetamide **477575-31-8P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-diethylaminoethyl)acetamide **477575-32-9P**, 2-[5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
2,4-dimethyl-1H-pyrrol-3-yl]-N-methyl-N-(1-methylpiperidin-4-yl)acetamide **477575-34-1P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-(pyrrolidin-1-yl)ethyl)acetamide **477575-37-4P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-hydroxy-3-(morpholin-4-yl)propyl)acetamide **477575-38-5P**, 2-[5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-hydroxy-3-[1,2,3]triazol-1-ylpropyl)acetamide **477575-46-5P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-methoxyethyl)amide **477575-47-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-methoxypropyl)amide **477575-48-7P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-hydroxyethoxy)ethyl]amide **477575-49-8P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-1-methylethyl)amide **477575-50-1P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amide **477575-57-8P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(morpholin-4-yl)ethyl)amide **477575-58-9P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(morpholin-4-yl)propyl)amide **477575-64-7P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylsulfanylethyl)amide **477575-65-8P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2,2,2-trifluoroethyl)amide **477575-86-3P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-2-yl)ethyl)amide **477575-89-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-3-yl)ethyl)amide **477575-90-9P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-4-yl)ethyl)amide **477575-91-0P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [(tetrahydrofuran-2-yl)methyl]amide **477575-92-1P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (cyclopropylmethyl)amide **477576-04-8P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-fluoroethyl)amide **477576-05-9P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl)amide **477576-06-0P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid methylamide **477576-07-1P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid amide **477576-09-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-acetylpiperazin-1-yl)ethyl]amide **477576-25-3P**, 3-[1-[4-[[(Cyclopropyl)methylamino]methyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-34-4P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3-acetylaminopyrrolidin-1-yl)ethyl]amide **477576-38-8P**, 2-[5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethyl]acetamide **477576-44-6P**, 2-[5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-

2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(2,2,2-trifluoroethylamino)ethyl]acetamide **477576-45-7P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-

1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2,2,2-trifluoroethylamino)ethyl]amide **477576-51-5P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(pyrrolidin-1-yl)propyl)amide **477576-52-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-cyclopropylamino-2-hydroxypropyl)amide **477576-55-9P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid cyclopropylamide **477576-56-0P**, N-[2-(3-Acetylaminopyrrolidin-1-yl)ethyl]-2-[5-[5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetamide **477576-57-1P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethyl]amide **477576-61-7P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-hydroxy-3-(pyrrolidin-1-yl)propyl)acetamide **477576-62-8P**, N-(3-Cyclopropylamino-2-hydroxypropyl)-2-[5-[5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetamide **477576-95-7P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-fluoropiperidin-1-yl)ethyl]amide **477576-98-0P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(4-fluoropiperidin-1-yl)ethyl]acetamide **477577-16-5P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3-fluoropyrrolidin-1-yl)ethyl]amide **477577-17-6P**, 2-[5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-

2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(3-fluoropyrrolidin-1-yl)ethyl]acetamide **477577-26-7P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-(2-amino-2-methylpropionyl)piperazin-1-yl)ethyl]amide **477577-31-4P**, N-[2-(4-Acetylpiperazin-1-yl)ethyl]-2-[5-[5-(2,6-

dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetamide **477577-33-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-hydroxypiperidin-1-yl)ethyl]amide **477577-35-8P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(4-hydroxypiperidin-1-yl)ethyl]acetamide **477577-40-5P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [(1-methylpiperidin-4-yl)methyl]amide **477577-42-7P**, 2-[5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]acetamide **477577-54-1P**, 3-[1-[4-[[(Cyclopropyl)methylamino]methyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-[2-(2-(morpholin-4-yl)ethoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477577-65-4P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid cyclopropyl((R)-1-pyrrolidin-2-ylmethyl)amide **477577-66-5P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (cyclopropylmethyl)((R)-1-pyrrolidin-2-ylmethyl)amide **477577-96-1P**, 4-(4-Fluorophenyl)-2-methyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477578-01-1P**, 5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(3-(pyrrolidin-1-yl)propyl)amide
477578-03-3P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3-fluoropiperidin-1-yl)ethyl]amide **477578-07-7P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(3-fluoropiperidin-1-yl)ethyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and
other disorders)
RN 477573-60-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-61-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-62-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477573-69-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-5-[[(2-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-74-3 CAPLUS
CN Benzoic acid,
4-[[[(3E)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 477573-63-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[(3-methoxyphenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-67-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[(2-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-68-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477573-75-4 CAPLUS
CN Benzeneacetic acid,
4-[[[(3Z)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NEt2

RN 477573-76-5 CAPLUS
CN Benzoic acid,
4-[[[(3Z)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477573-78-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(3,5-dibromo-2-hydroxyphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-79-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 477573-82-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-83-4 CAPLUS
CN Benzoic acid, 4-[[[(3Z)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NEt2

RN 477573-84-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477573-80-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-4-methyl-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-81-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—NEt2

RN 477573-86-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[2,4-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-88-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(4-bromophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477573-89-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[(2-iodophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-91-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(4-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-93-6 CAPLUS
CN Benzoic acid,
3-[[[(3Z)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 477573-96-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[3-(trifluoromethoxy)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 477573-98-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(3-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-00-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[(3-methylphenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-02-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(2,4-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 477574-04-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-06-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-08-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-11-1 CAPLUS

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[(4-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-13-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[(3-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-14-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(3-bromophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477574-16-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(3,5-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-18-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(3,4-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 477574-20-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[[2,5-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-22-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-24-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[(2-hydroxy-5-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477574-26-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[(2-methoxy-5-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-28-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-30-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(3-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-32-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(4-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-35-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477574-37-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-40-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[(pentafluorophenyl)methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 477574-42-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(2,5-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-44-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[(2,3,6-trifluorophenyl)methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-46-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(2,3-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477574-47-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-49-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[([1,1'-biphenyl]-2-ylmethyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-51-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(2-fluoro-6-nitrophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-53-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[[2-(2-fluorophenoxy)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-55-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(4-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477574-65-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-66-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-[bis(1-methylethyl)amino]ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-67-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 477574-59-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-60-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-64-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



RN 477574-68-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-70-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[(Z)-[5-[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 477574-74-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-77-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-78-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[(Z)-[5-[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—N(Pr-i)$_2$

RN 477574-88-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-89-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477574-90-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-11-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-hydroxyethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 477575-16-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-22-7 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-31-8 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477575-32-9 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-34-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477575-37-4 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-38-5 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477575-46-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-methoxyethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-47-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(3-methoxypropyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-48-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(2-hydroxyethoxy)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 477575-49-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-50-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477575-57-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-
morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-
morpholinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477575-64-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(ethylthio)ethyl]-2,4-
dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-65-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-(2,2,2-
trifluoroethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-86-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(2-
pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-89-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(3-
pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-90-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-
pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477575-91-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-

1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(tetrahydro-2-
furanyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-92-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(cyclopropylmethyl)-5-[(Z)-[5-[[(2,6-
dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 477576-04-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-fluoroethyl)-2,4-
dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-05-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1H-imidazol-1-
yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-06-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477576-07-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.



RN 477576-09-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-[5-
[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477576-25-3 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(cyclopropylmethylamino)methyl]-3,5-dimethyl-1H-
pyrrol-2-yl]methylene]-5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,3-
dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-34-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[3-(acetylamino)-1-pyrrolidinyl]ethyl]-5-
[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477576-38-8 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-[4-(hydroxyacetyl)-1-
piperazinyl]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 477576-44-6 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-[(2,2,2-
trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477576-45-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-[(2,2,2-
trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-51-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-
pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—NHAc

RN 477576-57-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-[4-(hydroxyacetyl)-1-
piperazinyl]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—OH

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 477576-52-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(cyclopropylamino)-2-hydroxypropyl]-5-[(Z)-
[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-55-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-5-[(Z)-[5-[[(2,6-
dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-56-0 CAPLUS
CN 1H-Pyrrole-3-acetamide,
N-[2-[3-(acetylamino)-1-pyrrolidinyl]ethyl]-5-[(Z)-
[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 477576-61-7 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-
pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-62-8 CAPLUS
CN 1H-Pyrrole-3-acetamide,
N-[3-(cyclopropylamino)-2-hydroxypropyl]-5-[(Z)-[5-
[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-95-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(4-fluoro-1-
piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477576-98-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(4-fluoro-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-16-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—NH_2

RN 477577-31-4 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-33-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477577-17-6 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-26-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[4-(2-amino-2-methyl-1-oxopropyl)-1-piperazinyl]ethyl]-5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(4-hydroxy-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-35-8 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(4-hydroxy-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—OH

RN 477577-40-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-42-7 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-54-1 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(cyclopropylmethylamino)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-[[[2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]sulfonyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477577-65-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-66-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(cyclopropylmethyl)-5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 477577-96-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-4-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477578-01-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477578-03-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(3-fluoro-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



RN 477578-07-7 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(3-fluoro-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **477576-37-7P**, 4-[2-[[2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]amino]ethyl]piperazine-1-carboxylic acid tert-butyl ester **477576-39-9P**, Acetic acid 2-[4-[2-[[2-[5-[5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]amino]ethyl]piperazin-1-yl]-2-oxoethyl ester **477576-58-2P**, 4-[2-[[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-ylcarbonyl]amino]ethyl]piperazine-1-carboxylic acid tert-butyl ester **477576-59-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(piperazin-1-yl)ethyl)amide **477576-60-6P**, Acetic acid 2-[4-[2-[[5-[5-(2,6-

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-

2,4-dimethyl-1H-pyrrol-3-ylcarbonyl]amino}ethyl]piperazin-1-yl}-2-oxoethyl ester 477577-27-8P, {2-[4-[2-[[5-[5-(2,6-

Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-ylcarbonyl]amino}ethyl]piperazin-1-yl]-1,1-dimethyl-2-oxoethyl]carbamic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)

RN 477576-37-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[[[5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 477576-39-9 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-[4-[(acetyloxy)acetyl]-1-piperazinyl]ethyl]-5-

[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 477576-59-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-60-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[4-[(acetyloxy)acetyl]-1-piperazinyl]ethyl]-5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 477576-58-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[[[5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 477577-27-8 CAPLUS
CN Carbamic acid, [2-[4-[2-[[[5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 53 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L4 ANSWER 54 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:805222 CAPLUS
DOCUMENT NUMBER: 139:270353
TITLE: Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. [Erratum to document cited in CA138:147266]
AUTHOR(S): Liao, Albert T.; Chien, May B.; Shenoy, Narmada; Mendel, Dirk B.; McMahon, Gerald; Cherrington, Julie M.; London, Cheryl A.
CORPORATE SOURCE: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California at Davis, Davis, CA, 95616, USA
SOURCE: Blood (2002), 100(8), 2696
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In "Materials and methods", under "Antibodies", the fifth sentence should refer to "anti-phosphatidyl inositol 3-kinase.".
IT **326914-10-7**, SU 11652 **356068-94-5**, SU 11654 **356069-35-7**, SU 11655
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors (Erratum))
RN 326914-10-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 54 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-35-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:793619 CAPLUS
DOCUMENT NUMBER: 137:294870
TITLE: Preparation of prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinones and activity as modulators of protein kinases
INVENTOR(S): Sun, Connie Li; Wei, Chung Chen; Tang, Peng Cho; Koenig, Marcel; Zhou, Yong; Vojkovsky, Tomas; Nematalla, Asaad S.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081466	A1	20021017	WO 2002-US11001	20020409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003100555	A1	20030529	US 2002-118321	20020409
US 6797725	B2	20040928		
US 2004186161	A1	20040923	US 2004-816957	20040405
PRIORITY APPLN. INFO.:			US 2001-282630P	P 20010409
			US 2002-118321	A3 20020409

OTHER SOURCE(S): MARPAT 137:294870
GI



I

AB The present invention relates to pyrrole substituted 2-indolinone compds. (shown as I; e.g. 3-[1-(3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydroindole-1-carbonyl chloride) and their pharmaceutically

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer (no data). In I,
R1 and R2 are independently H, halo, alkyl, alkylthio, nitro, trihalomethyl, hydroxy, hydroxyalkyl, alkoxy, cyano, aryl, heteroaryl, -C(O)R7 (R7 is alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, heterocycle, and aminoalkylamino), -NR8R9, -NR8C(O)R9, -SO2R8, and -S(O)2NR8R9 (R8 and R9 are independently H, alkyl, aryl and heteroaryl, or R8 and R9 together with the N to which they are attached form a satd. heterocycloamino). R3 is H, alkyl, hydroxyalkyl, aminoalkyl,
-C(O)R7, aryl, and heteroaryl; R4 is H, alkyl, -C(O)R7 aryl, and heteroaryl. R5 is H and -COR10 where R10 is alkyl, alkoxy, hydroxy, aryl,
aryloxy, heteroaryl, heterocycle, alkylamino, dialkylamino, or -NR11R12 where R11 is H or alkyl, and R12 is aminoalkyl, hydroxyalkyl, acetylalkyl,
cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s); or R4 and R5 together form - (CH2)4- or -(CH2)mCO(CH2)n- wherein n is 0 to 3, provided that n+m is 3. R6 is: (c) -OR13 wherein R13 is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocyclyl, monosaccharides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in said alkyl chain are optionally replaced by O, -NR14- (R14 is H or alkyl), -S-, or -SO2-; or. (d) -NR15R16 where are R15 and R16 are independently H, alkyl,
carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, aryl, heteroaryl, heteroaralkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in the alkyl chain are optionally replaced by O, -NR17- (R17 is H or alkyl), -S-, or -SO2-; or R15 and R16 together with
the N atom to which they are attached form satd. or unsatd. heterocycloamino;. Although the methods of prepn. are not claimed, >80 example prepns. are included, both of I and the unprotected version of I in which the C(O)R6 group has been replaced by H.

IT **356068-94-5P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of prodrugs of (pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)

RN 356068-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **557795-19-4P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase modulator; preparation of prodrugs of (pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)

RN 557795-19-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **342641-49-0P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-50-3P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide **342641-51-4P**,

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-52-5P**,

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid [3-(4-methylpiperazin-1-yl)propyl]amide **342641-54-7P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-55-8P**, 5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-56-9P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **342641-57-0P**,

5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **342641-59-2P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-60-5P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **342641-61-6P**, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **342641-62-7P**, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **342641-63-8P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-64-9P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-65-0P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl)amide **342641-66-1P**, 5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **342641-67-2P**, 5-[6-(3-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **342641-68-3P**, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-69-4P**, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-70-7P**, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl)amide **342641-71-8P**, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-72-9P**, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-73-0P**, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl)amide **342641-74-1P**, 5-[6-(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-75-2P**, 2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-76-3P**, 2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-77-4P**,

2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide **342641-78-5P**, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide **342641-79-6P**, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-80-9P**, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-81-0P**, 3-[4-(3-Diethylaminopropylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)amide **342641-82-1P**,

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-83-2P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-84-3P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-85-4P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide **342641-87-6P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide **342641-88-7P**, 5-[6-(4-Butylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-89-8P**,

5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-91-2P**, 5-[6-(4-Ethylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-92-3P**, 5-[6-(2,4-Dimethoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-93-4P**, 5-[6-(3-Isopropylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-94-5P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-95-6P**, 3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid **342641-96-7P**, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-97-8P**,

5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-98-9P**, 2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342642-01-7P**, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342642-02-8P**, 5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342642-09-5P**, [[4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]amino]acetic acid ethyl ester **342642-10-8P**,

[[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]amino]acetic acid ethyl ester **342642-11-9P**,

[[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]amino]acetic acid **346405-32-1P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **356068-82-1P**, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **356068-90-1P**, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **356068-91-2P**, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **356068-92-3P**, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ethyl)amide **356068-95-6P**, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **356068-96-7P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide **356068-97-8P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)amide **356068-99-0P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoaminoethyl)amide **356069-03-9P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide **356069-04-0P**, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide **356069-05-1P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide **356069-07-3P**, 5-(2-Oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide **356069-09-5P**, 5-(2-Oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide **356069-12-0P**, 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl]ethyl]amide **356069-13-1P**, 5-(5-Chloro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide **356069-15-3P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide **468745-38-2P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(pyridin-2-yl)ethyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase modulator; prepn. of prodrugs of (pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)

RN 342641-49-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-50-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 342641-51-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-2-(1-methylethyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-54-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-57-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-66-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 342641-68-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-71-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-
6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-72-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX
NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-73-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-
ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA
INDEX NAME)



RN 342641-74-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA
INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-75-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-
6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX
NAME)



RN 342641-76-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-
ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX
NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-77-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-
ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA
INDEX
NAME)



RN 342641-78-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-
ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA
INDEX
NAME)



L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 342641-79-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-
5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-80-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-
6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-81-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-
(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-
yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX
NAME)



RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI)
(CA INDEX NAME)



RN 342641-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(CA INDEX NAME)



RN 342641-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]-
(9CI)
(CA INDEX NAME)



RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX
NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-88-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)



RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-
methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-
pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-95-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 342641-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342642-01-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-09-5 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-10-8 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342642-11-9 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 356068-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-90-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-95-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356068-99-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-03-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-04-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-05-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-07-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-09-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
(9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 356069-13-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-15-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 468745-38-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 55 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:658111 CAPLUS
DOCUMENT NUMBER: 137:185408
TITLE: 3-(4-Amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
INVENTOR(S): Guan, Huiping; Liang, Congxin; Sun, Li; Tang, Peng Cho; Wei, Chung Chen; Mauragis, Michael A.; Vojkovsky, Tomas; Jin, Qingwu; Herrinton, Paul Matthew
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066463	A1	20020829	WO 2002-US4407	20020215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438314	AA	20020829	CA 2002-2438314	20020215
US 2003092917	A1	20030515	US 2002-76140	20020215
US 6653308	B2	20031125		
EP 1370554	A1	20031217	EP 2002-714897	20020215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300385	A	20040216	EE 2003-385	20020215
BR 2002007494	A	20040427	BR 2002-7494	20020215
JP 2004522776	T2	20040729	JP 2002-565978	20020215
WO 2003070725	A2	20030828	WO 2003-US4520	20030214
WO 2003070725	A3	20040115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003229229	A1	20031211	US 2003-367008	20030214
EP 1476443	A2	20041117	EP 2003-742760	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
NO 2003003608	A	20031014	NO 2003-3608	20030814
US 2004102510	A1	20040527	US 2003-656907	20030908
PRIORITY APPLN. INFO.:			US 2001-268683P P	20010215
			US 2001-312361P P	20010815

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 2002-76140	A3	20020215
WO 2002-US4407	W	20020215
US 2002-411732P	P	20020918
WO 2003-US4520	W	20030214

OTHER SOURCE(S): MARPAT 137:185408
GI



I



II

AB Title compds. I [R1 = H, halo, alkyl, haloalkoxy, cycloalkyl, heterocyclic, OH, alkoxy, (un)esterified CO2H, (un)substituted NH2, CONH2; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (un)substituted NH2, SO2NH2, (un)esterified CO2H, SO2R8, R8 = alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; R3-R6 = H, alkyl; R7 = H, alkyl, aryl, heteroaryl, acyl; Z = aryl, heteroaryl, heterocyclic, (un)substituted NH2] were prepared for use as protein kinase inhibitors in treatment of diseases, such as cancer (no data). Thus, Et 3,5-dimethyl-4-pyrrolecarboxylate was oxidized to the 5-carboxaldehyde, followed by ester hydrolysis, reaction with 5-fluoro-2-oxindole and amidation to give the amide II.

IT 375798-55-3P 452104-42-6P 452104-43-7P
452104-44-8P 452104-45-9P 452104-46-0P
452104-47-1P 452104-48-2P 452104-49-3P
452104-50-6P 452104-51-7P 452104-52-8P
452104-53-9P 452104-54-0P 452104-55-1P

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
452104-56-2P 452104-57-3P 452104-58-4P
452104-59-5P 452104-60-8P 452104-61-9P
452104-62-0P 452104-63-1P 452104-64-2P
452104-65-3P 452104-66-4P 452104-67-5P
452104-68-6P 452104-69-7P 452104-70-0P
452104-71-1P 452104-72-2P 452104-73-3P
452104-74-4P 452104-75-5P 452104-76-6P
452104-77-7P 452104-78-8P 452104-79-9P
452104-80-2P 452104-81-3P 452104-82-4P
452104-83-5P 452104-84-6P 452104-85-7P
452104-86-8P 452104-87-9P 452104-88-0P
452104-89-1P 452104-90-4P 452104-91-5P
452104-92-6P 452104-93-7P 452104-94-8P
452104-95-9P 452104-96-0P 452104-97-1P
452104-98-2P 452104-99-3P 452105-00-9P
452105-01-0P 452105-02-1P 452105-03-2P
452105-04-3P 452105-05-4P 452105-06-5P
452105-07-6P 452105-08-7P 452105-09-8P
452105-10-1P 452105-11-2P 452105-12-3P
452105-13-4P 452105-14-5P 452105-15-6P
452105-16-7P 452105-17-8P 452105-18-9P
452105-19-0P 452105-20-3P 452105-21-4P
452105-22-5P 452105-23-6P 452105-24-7P
452105-25-8P 452105-26-9P 452105-27-0P
452105-28-1P 452105-29-2P 452105-30-5P
452105-31-6P 452105-32-7P 452105-44-1P
452105-45-2P 452105-46-3P 452105-47-4P
452105-62-3P 452105-63-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivs. as protein kinase inhibitors)
RN 375798-55-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-42-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-43-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-44-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-45-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-46-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-47-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-48-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-49-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-50-6 CAPLUS

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-53-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 452104-54-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 452104-55-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(4-fluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-51-7 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 452104-52-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-56-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 452104-57-3 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 452104-58-4 CAPLUS

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Indole-5-carboxamide, 3-[[3-(4-cyanophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 452104-59-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(4-cyanophenyl)-N-[3-(diethylamino)-2-hydroxypropyl]-5-[[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 452104-60-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[3-(4-chlorophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-61-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[3-(4-chlorophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 452104-62-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-63-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-64-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-65-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-66-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-67-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-(2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-68-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2,6-dimethyl-4-morpholinyl)-2-

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 452104-70-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-71-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-69-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-72-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-73-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-74-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-75-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-76-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-77-7 CAPLUS

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-78-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 452104-79-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 452104-80-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 452104-81-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 452104-82-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 452104-83-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 452104-84-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 452104-85-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-86-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-87-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-88-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-89-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-90-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-91-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-92-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-93-7 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-94-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452104-95-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-96-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-97-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
hydroxypropyl]amino]carbonyl]-3-(4-fluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-98-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-99-3 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-00-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[3-(4-cyanophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-01-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(4-cyanophenyl)-N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 452105-02-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[3-(4-chlorophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-03-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[3-(4-chlorophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-04-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-05-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-06-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-07-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-08-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-09-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-10-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-11-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452105-12-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452105-13-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-14-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-15-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-16-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-17-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-18-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-19-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-20-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-21-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-22-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-25-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-26-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-27-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-28-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-31-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 452105-32-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 452105-29-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 452105-30-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 452105-44-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-45-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-46-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry as shown.



RN 452105-47-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-62-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-63-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl-

L4 ANSWER 56 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 57 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:541364 CAPLUS
DOCUMENT NUMBER: 138:147266
TITLE: Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors
AUTHOR(S): Liao, Albert T.; Chien, May B.; Shenoy, Narmada; Mendel, Dirk B.; McMahon, Gerald; Cherrington, Julie M.; London, Cheryl A.
CORPORATE SOURCE: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California at Davis, Davis, CA, 95616, USA
SOURCE: Blood (2002), 100(2), 585-593
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Mutations in the proto-oncogene c-kit, including point mutations, deletions, or duplications in the neg. regulatory juxtamembrane (JM) domain or point mutations in the catalytic domain, have been observed in human and canine cancers and often result in constitutive activation of Kit in the absence of ligand binding. To identify a receptor tyrosine kinase (RTK) inhibitor capable of blocking the function of mutant Kit, we evaluated 3 indolinones (SU11652, SU11654, and SU11655) that act as competitive inhibitors of ATP binding to several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. Mast cell lines expressing either wildtype (WT) Kit, a point mutation in the JM domain, a tandem duplication in the JM domain, or a point mutation in the catalytic domain were used for these studies. All 3 indolinones inhibited phosphorylation of WT Kit in the presence of stem cell factor at concns. as low as 0.01 μM. Autophosphorylation of both JM mutants was inhibited at 0.01 to 0.1 μM, resulting in cell cycle arrest within 24 h, whereas autophosphorylation of the catalytic domain mutant was inhibited at 0.25 to 0.5 μM, resulting in cell death within 24 h. Poly(ADP-ribose) polymerase (PARP) cleavage was noted in all Kit mutant lines after indolinone treatment. In summary, SU11652, SU11654, and SU11655 are effective RTK inhibitors capable of disrupting the function of all forms of mutant Kit. Because the concns. of drug necessary for receptor inhibition are readily achievable and nontoxic in vivo, these compds. may be useful in the treatment of spontaneous cancers expressing Kit mutations.
IT **326914-10-7**, SU 11652 **356068-94-5**, SU 11654 **356069-35-7**, SU 11655
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors)
RN 326914-10-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 57 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-35-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 57 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:539677 CAPLUS
DOCUMENT NUMBER: 137:109202
TITLE: Preparation of 4-aryl substituted indolinones as protein kinase signal transduction modulators for inhibiting abnormal cell proliferation
INVENTOR(S): Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung Chen; Tang, Peng Cho
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 560 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055517	A2	20020718	WO 2001-US48564	20011220
WO 2002055517	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432114	AA	20020718	CA 2001-2432114	20011220
US 2003069297	A1	20030410	US 2001-23488	20011220
US 6677368	B2	20040113		
EP 1349852	A2	20031008	EP 2001-997065	20011220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518669	T2	20040624	JP 2002-556186	20011220
US 2004157909	A1	20040812	US 2003-736243	20031216

PRIORITY APPLN. INFO.: US 2000-256479P P 20001220
US 2001-23488 A3 20011220
WO 2001-US48564 W 20011220

OTHER SOURCE(S): MARPAT 137:109202
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocyclyl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compns. thereof, are prepd. and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepd. via condensation of 4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl]propyl]-1H-pyrrole-3-carboxylic acid Et ester. I were evaluated against eight specfic kinases, e.g., FGFR1, for which I possessed IC50 values (μM) of 0.0091-2.07. The present invention also relates to methods for treating protein kinase related disorders.

IT **442558-05-6P 442558-07-8P 442558-08-9P**
442558-09-0P 442558-15-8P 442558-16-9P
442558-17-0P 442558-23-8P 442558-24-9P
442558-25-0P 442558-31-8P 442558-32-9P
442558-33-0P 442558-39-6P 442558-40-9P
442558-41-0P 442558-48-7P 442558-49-8P
442558-50-1P 442558-54-5P 442558-56-7P
442558-57-8P 442558-58-9P 442558-62-5P
442558-63-6P 442558-65-8P 442558-66-9P
442558-67-0P 442558-71-6P 442558-88-5P
442558-89-6P 442558-90-9P 442558-91-0P
442558-92-1P 442558-93-2P 442558-94-3P
442558-96-5P 442558-97-6P 442558-98-7P
442559-03-7P 442559-05-9P 442559-07-1P
442559-08-2P 442559-09-3P 442559-14-0P
442559-19-5P 442559-20-8P 442559-42-4P
442559-43-5P 442559-53-7P 442559-54-8P
442559-55-9P 442559-57-1P 442559-79-7P
442559-80-0P 442559-97-9P 442559-98-0P
442559-99-1P 442560-00-1P 442560-01-2P
442560-02-3P 442560-03-4P 442560-04-5P
442560-07-8P 442560-09-0P 442560-10-3P
442560-11-4P 442560-14-7P 442560-22-7P
442560-25-0P 442560-26-1P 442560-27-2P
442560-29-4P 442560-39-6P 442560-43-2P
442560-44-3P 442560-51-2P 442560-64-7P
442560-65-8P 442560-66-9P 442560-69-2P
442560-79-4P 442560-80-7P 442560-81-8P
442560-83-0P 442560-88-5P 442561-01-5P
442561-06-0P 442561-07-1P 442561-11-7P
442561-12-8P 442561-13-9P 442561-39-9P
442561-48-0P 442561-52-6P 442561-53-7P
442561-54-8P 442561-55-9P 442561-56-0P
442561-76-4P 442561-77-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)

RN 442558-05-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-4-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-07-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-08-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-09-0 CAPLUS

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-15-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-16-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-24-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-25-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-17-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-23-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-31-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-32-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-33-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-39-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-40-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-41-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-48-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-49-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-50-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-54-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-56-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX
NAME)



RN 442558-57-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI)
(CA INDEX NAME)



RN 442558-62-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[[4-(4-
bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-63-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX
NAME)



RN 442558-65-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA
INDEX
NAME)



RN 442558-66-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-67-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-
3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI)
(CA INDEX NAME)



RN 442558-71-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[[4-(3-
bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-88-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-89-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-90-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-91-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-92-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-93-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
NAME)



RN 442558-94-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX
NAME)



RN 442558-96-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-97-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442558-98-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442559-03-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-05-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442559-07-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442559-08-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-19-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442559-20-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-09-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442559-14-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-42-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442559-43-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-53-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(Z)-[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-54-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-79-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-80-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-55-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-57-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-97-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-98-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442559-99-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-00-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-(4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-01-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-02-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 442560-03-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-04-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-07-8 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-09-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-10-3 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-11-4 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-14-7 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-22-7 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-25-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-26-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-27-2 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-29-4 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-39-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-(4-[1,1'-biphenyl]-3-yl-1,2-dihydro-2-oxo-
3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-
2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-43-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-64-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-N-methyl-N-(1-methyl-4-piperidinyl)-4-phenyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-65-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-(2-
fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-phenyl-
(9CI)
(CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-44-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-(4-[1,1'-biphenyl]-2-yl-1,2-dihydro-2-oxo-
3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 442560-51-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3,5-difluorophenyl)-1,2-dihydro-2-oxo-
3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-
(9CI)
(CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-66-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.



RN 442560-69-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-[3-[2-
(dimethylamino)-2-oxoethyl]phenyl]-1,2-dihydro-2-oxo-3H-indol-3-
ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-79-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-80-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-amino-1H-indazol-5-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-81-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-amino-1H-indazol-5-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442560-83-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442560-88-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2,4-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-01-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442561-06-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-07-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442561-11-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-12-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442561-48-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-52-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-[(methylamino)carbonyl]phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442561-13-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-39-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethoxy)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442561-53-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-54-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-55-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 442561-56-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 58 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 442561-76-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-77-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 59 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:31440 CAPLUS
DOCUMENT NUMBER: 136:102386
TITLE: Preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Wei, Chung Chen; Huang, Ping; Cui, Jingron
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002551	A1	20020110	WO 2001-US20768	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414468	AA	20020110	CA 2001-2414468	20010629
US 2002187978	A1	20021212	US 2001-894902	20010629
US 6635640	B2	20031021		
EP 1296975	A1	20030402	EP 2001-948830	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502686	T2	20040129	JP 2002-507803	20010629
US 2004097497	A1	20040520	US 2003-648810	20030827
PRIORITY APPLN. INFO.:			US 2000-215654P	P 20000630
			US 2001-894902	A3 20010629
			WO 2001-US20768	W 20010629

OTHER SOURCE(S): MARPAT 136:102386
GI



I



II

L4 ANSWER 59 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, etc.; Het = (un)substituted aromatic heterocycle containing at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted aromatic heterocycle containing not more than two N atoms, 5-membered ring (un)substituted heterocycle containing N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.} with some exceptions, were prepared Included are 75 synthetic examples and results for several protein tyrosine kinase assays for those compds. For instance, 4-bromoindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf)•CH2Cl2, 80°C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine•HCl (THF, Pd(PPh3)4, NaOH, 70°C, 6 h) to give the indole which was treated with C5H5N•Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dyhydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 mM for FGFR-1 tyrosine kinase and 0.03 mM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.

IT **388116-64-1P 388116-68-5P 388116-99-2P 388117-02-0P 388117-08-6P 388117-10-0P 388117-12-2P 388117-28-0P 388117-30-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-64-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-68-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 59 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 388117-08-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 388117-10-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 59 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 388116-99-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-02-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 59 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 388117-12-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 388117-28-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 59 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 60 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:868415 CAPLUS
DOCUMENT NUMBER: 136:697
TITLE: Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
INVENTOR(S): Moon, Malcolm Wilson; Morozowich, Walter; Gao, Ping; Tang, Peng Cho
PATENT ASSIGNEE(S): Sugen, Inc., USA; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090068	A2	20011129	WO 2001-US16757	20010524
WO 2001090068	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408709	AA	20011129	CA 2001-2408709	20010524
AU 2001064885	A5	20011203	AU 2001-64885	20010524
US 2002032204	A1	20020314	US 2001-863804	20010524
US 6710067	B2	20040323		
US 2002035140	A1	20020321	US 2001-863905	20010524
US 6451838	B2	20020917		
US 2002037878	A1	20020328	US 2001-863819	20010524
US 6482848	B2	20021119		
EP 1301507	A2	20030416	EP 2001-939357	20010524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003534323	T2	20031118	JP 2001-586257	20010524
US 2003045565	A1	20030306	US 2002-243663	20020916
US 2003083363	A1	20030501	US 2002-243942	20020916
US 6716870	B2	20040406		
US 2004127542	A1	20040701	US 2003-429895	20030505
US 2004127544	A1	20040701	US 2003-743909	20031224

PRIORITY APPLN. INFO.:

US 2000-207000P	P	20000524
US 2000-225045P	P	20000811
US 2001-863804	A1	20010524
US 2001-863819	A3	20010524
US 2001-863905	A1	20010524

L4 ANSWER 60 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

WO 2001-US16757	W	20010524
US 2002-243663	B1	20020916

OTHER SOURCE(S): MARPAT 136:697

AB The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. that modulate the activity of protein kinases ("PKs"). Pharmaceutical compns. comprising these compds., methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compns. comprising these compds. and methods of preparing them are also disclosed.

IT **557795-19-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 557795-19-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **375798-55-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 375798-55-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:617993 CAPLUS
DOCUMENT NUMBER: 135:195497
TITLE: Preparation of pyrrole substituted 2-indolinone protein kinase inhibitors for treatment of cancer
INVENTOR(S): Tang, Peng Cho; Miller, Todd; Li, Xiaoyuan; Sun, Li; Wei, Chung Chen; Shirazian, Shahrzad; Liang, Congxin; Vojkovsky, Tomas; Nematalla, Asaad S.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060814	A2	20010823	WO 2001-US4813	20010215
WO 2001060814	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2399358	AA	20010823	CA 2001-2399358	20010215
US 2002156292	A1	20021024	US 2001-783264	20010215
US 6573293	B2	20030603		
EP 1255752	A2	20021113	EP 2001-914376	20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523340	T2	20030805	JP 2001-560198	20010215
BR 2001008394	A	20040622	BR 2001-8394	20010215
NO 2002003831	A	20021015	NO 2002-3831	20020813
ZA 2002006469	A	20031113	ZA 2002-6469	20020813
BG 107078	A	20030430	BG 2002-107078	20020910
US 2004063773	A1	20040401	US 2003-412690	20030414

PRIORITY APPLN. INFO.:

US 2000-182710P	P	20000215
US 2000-216422P	P	20000706
US 2000-243532P	P	20001027
US 2001-783264	A3	20010215
WO 2001-US4813	W	20010215

OTHER SOURCE(S): MARPAT 135:195497

GI

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB The title compds. (I) [wherein R1 = H, halo, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, OH, alkoxy, acyl, (un)substituted amino or carbamoyl, etc.; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (hetero)aryl, (un)substituted amino, acyl(amino), or sulfamoyl, etc.; R3 = H, halo, alkyl, trihalomethyl, OH, alkoxy, (hetero)aryl, (un)substituted acyl, (acyl)amino, sulfamoyl, or alkylsulfonyl, etc.; R4 = H, halo, alkyl, OH, alkoxy, or (un)substituted amino; R5 and R6 = independently H, alkyl, or acyl; R7 = H, alkyl, (hetero)aryl, or acyl; and their pharmaceutically acceptable salts] were prepared as protein kinase modulators for the treatment of cellular disorders such as cancer. For example, 5-fluoro-1,3-dihydroindol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give II (55%). II exhibited comparable activity against Flk-1 and PDGFRβ and inhibited PDGF-dependent receptor phosphorylation in cells with an IC50 value of approx. 0.03 μM. In efficacy expts. against various cancers in mice, II was well tolerated at 80 mg/kg/day, even when dosed continuously for more than 100 days.

IT **557795-19-4P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrole substituted 2-indolinone protein kinase inhibitors
by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 557795-19-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



IT **326914-09-4P 326914-10-7P 326914-17-4P**
326914-19-6P 342641-49-0P 342641-50-3P
342641-51-4P 342641-52-5P 342641-54-7P
342641-55-8P 342641-56-9P 342641-57-0P
342641-59-2P 342641-60-5P 342641-61-6P
342641-62-7P 342641-63-8P 342641-64-9P
342641-65-0P 342641-66-1P 342641-67-2P
342641-68-3P 342641-69-4P 342641-70-7P
342641-71-8P 342641-72-9P 342641-73-0P
342641-74-1P 342641-75-2P 342641-76-3P
342641-77-4P 342641-78-5P 342641-79-6P
342641-80-9P 342641-81-0P 342641-82-1P
342641-83-2P 342641-84-3P 342641-85-4P
342641-87-6P 342641-88-7P 342641-89-8P
342641-91-2P 342641-92-3P 342641-93-4P
342641-94-5P 342641-95-6P 342641-96-7P
342641-97-8P 342641-98-9P 342642-01-7P
342642-02-8P 342642-09-5P 342642-10-8P
342642-11-9P 346405-32-1P 356068-82-1P
356068-90-1P 356068-91-2P 356068-92-3P
356068-94-5P 356068-95-6P 356068-96-7P
356068-97-8P 356068-99-0P 356069-03-9P
356069-04-0P 356069-05-1P 356069-07-3P
356069-09-5P 356069-12-0P 356069-13-1P
356069-15-3P 356069-16-4P 356069-17-5P
356069-18-6P 356069-19-7P 356069-20-0P
356069-21-1P 356069-22-2P 356069-23-3P
356069-24-4P 356069-25-5P 356069-26-6P
356069-27-7P 356069-28-8P 356069-29-9P
356069-30-2P 356069-31-3P 356069-33-5P
356069-34-6P 356069-35-7P 356069-36-8P
356069-37-9P 356069-38-0P 356069-39-1P
356069-40-4P 356069-41-5P 356069-42-6P
356069-43-7P 356069-44-8P 356069-45-9P
356069-46-0P 356069-47-1P 356069-48-2P
356069-49-3P 356069-50-6P 356069-51-7P
356069-53-9P 356069-55-1P 356069-57-3P
356069-58-4P 356069-59-5P 356069-60-8P
356069-61-9P 356069-62-0P 356069-64-2P
356069-65-3P 356069-66-4P 356069-67-5P
356069-68-6P 356069-69-7P 356069-70-0P
356069-71-1P 356069-72-2P 356069-73-3P

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

356069-74-4P 356069-75-5P 356069-76-6P
356069-77-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 326914-09-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 326914-10-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 326914-17-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 326914-19-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 342641-49-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-50-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-51-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-54-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-57-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-68-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-66-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



RN 342641-71-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-72-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-73-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-74-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-77-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-78-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-75-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-76-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 342641-79-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-80-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-81-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 342641-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 342641-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 342641-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 342641-88-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-95-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342642-01-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 342641-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 342642-09-5 CAPLUS
CN Glycine, N-[[5-[(1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-10-8 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-11-9 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-90-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356068-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356068-95-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-97-8 CAPLUS

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356068-99-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-03-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-04-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-05-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 356069-09-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-13-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-07-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry as shown.



RN 356069-15-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-16-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-17-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethyloxidoamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-18-6 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-chloro-1,2-dihydro-2-

oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-82-1
CMF C22 H25 Cl N4 O2

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 356069-19-7 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5
CMF C22 H27 F N4 O2

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 356069-20-0 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-90-1
CMF C22 H27 Cl N4 O2



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-21-1 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-fluoro-1,2-dihydro-2-

oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 346405-32-1
CMF C22 H25 F N4 O2



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 356069-22-2 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 1

CRN 356069-16-4
CMF C20 H23 F N4 O2



CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 356069-23-3 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-99-0
CMF C22 H27 F N4 O3

Double bond geometry as shown.



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 2

CRN 97-67-6
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 356069-24-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-25-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-26-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-27-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-28-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-29-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-30-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-31-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-33-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-32-4
CMF C22 H24 Br N5 O3

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 356069-34-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 356069-35-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-36-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-37-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-38-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-39-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-40-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-41-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-42-6 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-43-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-44-8 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-45-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(cyanomethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-46-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-47-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-48-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-49-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-50-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-51-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-53-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-52-8
CMF C22 H24 F N5 O3

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 356069-55-1 CAPLUS

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 356069-58-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-59-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-54-0
CMF C22 H25 N5 O3

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 356069-57-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-56-2
CMF C23 H24 N6 O3

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-60-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-61-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-62-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-64-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-63-1
CMF C22 H24 Cl N5 O3

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 356069-65-3 CAPLUS

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-66-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-67-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-68-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-69-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 356069-70-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-71-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-72-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-73-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-74-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-75-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 61 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 356069-76-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-77-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 62 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:472477 CAPLUS
DOCUMENT NUMBER: 135:56059
TITLE: Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
INVENTOR(S): Lipson, Ken; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045689	A2	20010628	WO 2000-US35009	20001222
WO 2001045689	A3	20020103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395461	AA	20010628	CA 2000-2395461	20001222
US 2002010203	A1	20020124	US 2000-741842	20001222
EP 1255536	A2	20021113	EP 2000-991704	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500363	T2	20040108	JP 2001-546428	20001222
NZ 519697	A	20040827	NZ 2000-519697	20001222
US 2004002534	A1	20040101	US 2003-600868	20030623
PRIORITY APPLN. INFO.:			US 1999-171693P	P 19991222
			US 2000-741842	B1 20001222
			WO 2000-US35009	W 20001222

OTHER SOURCE(S): MARPAT 135:56059

AB The invention concerns indolinone compds. and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity of c-kit kinase.

IT **342641-94-5 346405-32-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(indolinone derivs. for c-kit tyrosine protein kinase function modulation)

RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 62 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:396655 CAPLUS
DOCUMENT NUMBER: 135:19549
TITLE: Preparation of pyrrole substituted 2-indolinones as antitumor agents
INVENTOR(S): Shenoy, Narmada; Sorasuchart, Waranush
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037820	A2	20010531	WO 2000-US32277	20001122
WO 2001037820	A3	20011213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1233943	A2	20020828	EP 2000-982228	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003514851	T2	20030422	JP 2001-539435	20001122
PRIORITY APPLN. INFO.:			US 1999-167544P	A1 19991124
			WO 2000-US32277	W 20001122

OTHER SOURCE(S): MARPAT 135:19549
GI



I

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, halo, alkyl, etc.; R3-R6 = H, alkyl, trihaloalkyl, etc.; R3 and R4, R4 and R5, R5 and R6 may combine to form a six membered aryl ring, OCH2O, OCH2CH2O; R7 = H, alkyl, cycloalkyl, etc.; R8-R10 = H, alkyl, trihaloalkyl, etc.] were prepared and formulated. E.g., a multi-step synthesis of I [R1-R7 = H; R8, R10 = Me; R9 = (CH2)2CO2H] which showed 79-86% inhibition of tumor growth of Calu-6 cells in mice at 75 and 100 mg/kg/day, was given. The present invention features formulations of indolinones which compds. are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term "ionizable substituted indolinone" includes pyrrole substituted 2-indolinones I which, in addition to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compound, are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group.

IT 251356-61-3P 251356-63-5P 251356-64-6P
251356-65-7P 251356-66-8P 251356-67-9P
251356-68-0P 251356-69-1P 251356-70-4P
251356-71-5P 251356-72-6P 251356-73-7P
251356-74-8P 251356-75-9P 251356-76-0P
251356-77-1P 251356-78-2P 342641-49-0P
342641-50-3P 342641-51-4P 342641-52-5P
342641-54-7P 342641-55-8P 342641-56-9P
342641-57-0P 342641-59-2P 342641-60-5P
342641-61-6P 342641-62-7P 342641-63-8P
342641-64-9P 342641-65-0P 342641-66-1P
342641-67-2P 342641-68-3P 342641-69-4P
342641-70-7P 342641-71-8P 342641-72-9P
342641-73-0P 342641-74-1P 342641-75-2P
342641-76-3P 342641-77-4P 342641-78-5P
342641-79-6P 342641-80-9P 342641-81-0P
342641-82-1P 342641-83-2P 342641-84-3P
342641-85-4P 342641-87-6P 342641-88-7P
342641-89-8P 342641-91-2P 342641-92-3P
342641-93-4P 342641-94-5P 342641-95-6P
342641-96-7P 342641-97-8P 342641-98-9P
342642-01-7P 342642-02-8P 342642-09-5P
342642-10-8P 342642-11-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrole substituted 2-indolinones as antitumor agents)

RN 251356-61-3 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251356-63-5 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-64-6 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 251356-65-7 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-66-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251356-67-9 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-68-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-69-1 CAPLUS
CN 2H-Indol-2-one, 6-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-70-4 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

yl]methylene]-1,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



RN 251356-71-5 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 251356-72-6 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 251356-73-7 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 251356-74-8 CAPLUS

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 251356-75-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-76-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-77-1 CAPLUS
CN Morpholine, 4-[[3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 251356-78-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 342641-49-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-50-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 342641-51-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-54-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-57-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-66-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-68-3 CAPLUS

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-71-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-72-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-73-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-74-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-77-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-78-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-75-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-76-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 342641-79-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-80-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-81-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 342641-82-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 342641-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 342641-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 342641-88-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 342641-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-95-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342642-01-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 342641-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-

L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 342642-09-5 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-10-8 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-11-9 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 64 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:688215 CAPLUS
DOCUMENT NUMBER: 133:252306
TITLE: Preparation of indolinones as protein kinase inhibitors.
INVENTOR(S): Tang, Peng Cho; Sun, Li; Mcmahon, Gerald; Miller, Todd
Anthony; Shirazian, Shahrzad; Wei, Chung Chen; Harris,
G. Davis; Xiaoyuan, Li; Liang, Congxin
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056709	A1	20000928	WO 2000-US7704	20000322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368041	AA	20000928	CA 2000-2368041	20000322
EP 1165513	A1	20020102	EP 2000-916622	20000322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002540096	T2	20021126	JP 2000-606571	20000322
US 6689806	B1	20040210	US 2000-534405	20000322
PRIORITY APPLN. INFO.:			US 1999-125945P	P 19990324
			US 1999-127863P	P 19990405
			US 1999-131192P	P 19990426
			US 1999-132243P	P 19990503
			WO 2000-US7704	W 20000322

OTHER SOURCE(S): MARPAT 133:252306
GI

L4 ANSWER 64 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB Title compds., e.g. [I; m, n = 0, 1; Q = (JR11)m; Q1 = (DR6)n; when n = 1,
then A, B, D, E, F = C, N; ≤3 of A, B, D, E, F = N; when m = 1,
then G, H, J, K, L = C, N; ≥1 and ≤3 of G, H, J, K, L = N;
when n = 0, then A = C, N, B, F = C, N, NH, O, S; E = C, N, O, S; when m = 0, then G = C, N, H, K, L = C, N, NH, O, S; R1-R13 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, SH, alkylthiol, aryloxy, amino, etc.; R4R5 or R5R6 or R6R7 or R7R8 = atoms
to form a 5-6 membered (hetero)aryl ring; with addnl. provisos], were prepared Thus, 6-pyridin-3-yl-1,3-dihydroindol-2-one (preparation given),
4-methoxy-3-thien-2-ylbenzaldehyde, and piperidine were refluxed overnight
in EtOH to give 15% 3-(4-methoxy-3-thien-2-ylbenzylidene)-6-pyridin-3-yl-1,3-dihydroindol-2-one. Tested title compds. inhibited HER2 kinase with IC50 = 16.4 μM to ≥100 μM.
IT **251356-74-8P 295799-29-0P 295799-47-2P**
295799-51-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolinones as protein kinase inhibitors)
RN 251356-74-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 64 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 295799-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-[2-[3-(1-methylethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 295799-47-2 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 295799-51-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-thienyl)- (9CI) (CA INDEX NAME)



IT **251356-61-3P 251356-63-5P 251356-65-7P**
251356-66-8P 251356-67-9P 251356-68-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolinones as protein kinase inhibitors)
RN 251356-61-3 CAPLUS

L4 ANSWER 64 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-63-5 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-65-7 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-66-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-67-9 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 64 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251356-68-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 65 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:764021 CAPLUS
DOCUMENT NUMBER: 132:12257
TITLE: Preparation of pyrrole substituted 2-indolinone protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 240 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961422	A1	19991202	WO 1999-US12069	19990528
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2314156	AA	19991202	CA 1999-2314156	19990528
AU 9944102	A1	19991213	AU 1999-44102	19990528
AU 759226	B2	20030410		
EP 1082305	A1	20010314	EP 1999-927120	19990528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9910792	A	20020129	BR 1999-10792	19990528
TR 200003514	T2	20020521	TR 2000-200003514	19990528
US 6395734	B1	20020528	US 1999-322297	19990528
JP 2002516310	T2	20020604	JP 2000-550828	19990528
NO 2000005916	A	20010129	NO 2000-5916	20001122
US 2003105151	A1	20030605	US 2002-81147	20020225
PRIORITY APPLN. INFO.:			US 1998-87310P	P 19980529
			US 1999-116106P	P 19990115
			US 1999-322297	A1 19990528
			WO 1999-US12069	W 19990528

OTHER SOURCE(S): MARPAT 132:12257
GI

L4 ANSWER 65 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB The present invention relates to 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid derivs. (I) [where R1 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, aryl, OH, alkoxy, carboxy, acetyl, (thio)amido, (trihalomethane)sulfonyl, etc.; R2 = H, halo, (cyclo)alkyl, (hetero)aryl, or heteroalicyclic; R3, R4, R5, R6, R8, R9, R10 = independently H, (cyclo)alkyl, trihaloalkyl, alkenyl, alkynyl, (hetero)aryl(oxy), heteroalicyclic, OH, alkoxy, SH, alkylthio, arylthio, sulfinyl, sulfonyl, sulfonamido , carbonyl, carboxy, amido, CN, NO2, halo, (thio)carbamyl, (un)substituted amino, etc.] which modulate the activity of protein kinases and are useful in the prevention and treatment of protein kinase related cellular disorders, such as cancer. Thus, 2,4-dimethyl-5-ethoxycarbonyl-3-(2-ethoxycarbonylethyl)pyrrole was deprotected using NaOH to form 3-(2-carboxyethyl)-2,4-dimethylpyrrole (100%) and the product C-5 formylated (two methods given for 86% and 90% yield, resp.). Reaction with 2-oxindole in EtOH and pyrrolidine or in aqueous NaOH yielded II (88% and 91%, resp.), which reduced the average size of C6 human glioma and melanoma tumors s.c. implanted in mice by 80-85%. II, when administered orally, demonstrated notably superior efficacy compared to structurally similar analogs.

IT **251356-61-3P 251356-63-5P 251356-64-6P 251356-65-7P 251356-66-8P 251356-67-9P 251356-68-0P 251356-69-1P 251356-70-4P 251356-71-5P 251356-72-6P 251356-73-7P 251356-74-8P 251356-75-9P 251356-76-0P 251356-77-1P 251356-78-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid protein kinase inhibitors as antitumor agents)

L4 ANSWER 65 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 251356-61-3 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-63-5 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-64-6 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 251356-65-7 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-66-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-

L4 ANSWER 65 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-67-9 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-68-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-69-1 CAPLUS
CN 2H-Indol-2-one, 6-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 65 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 251356-74-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 251356-75-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-76-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-77-1 CAPLUS
CN Morpholine, 4-[[3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 65 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 251356-70-4 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



RN 251356-71-5 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 251356-72-6 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 251356-73-7 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 65 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 251356-78-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

17/02/2005 10081147

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	324.70	489.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-47.45	-47.45

STN INTERNATIONAL LOGOFF AT 11:17:28 ON 17 FEB 2005